glycomark compendium of evidence
TRANSCRIPT
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
Glycemic Control
No. Title Institute Department First Author Citation 1 Variations of 1-Deoxyglucose (1,5-Anhydroglucitol)
content in patients with insulin-dependent diabetes mellitus
National Defense Medical College
Pediatrics Yoshioka S Clin.Chem 1983; 29(7): 1396-1398
2 Reduction and recovery of plasma 1,5-anhydro-D-glucitol level in diabetes mellitus
University of Teikyo Internal Medicine Yamanouchi T Diabetes 1987; 36(6): 709-715
3 Reduction of plasma 1,5-AG(1,5-Anhydroglucitol) levels in diabetes mellitus and renal glycosuria
Saitama Medical School
Internal Medicine Kawazu S J. Japan Diab. Soc. 1988; 31(8): 715-718
4 Urinary excretion of 1,5-Anhydro-D-glucitol accompanying glucose excretion in diabetic patients
Institute for Diabetes Care and Research, Asahi Life Foundation
Akanuma Y Diabetologia 1988; 31: 831-835
5 Reduction of plasma 1,5-anhydroglucitol concentration in diabetic patients
University of Teikyo Internal Medicine Yamanouchi T Diabetologia 1988; 31:41-45
6 Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients
University of Teikyo Internal Medicine Yamanouchi T Diabetes 1989; 38(6): 723-729
7 Clinical significance of serum 1,5-anhydroglucitol measurements in diabetes mellitus
University of Teikyo Internal Medicine Yamanouchi T J. Japan Diab. Soc. 1990; 33(1): 41-48
8 Serum 1,5-Anhydroglucitol level in patients with non-insulin-dependent diabetes Mellitus
Jichi Medical School Endocrinology and Metabolism
Iwamoto Y Korea Japan Symp.D.M. 1991; 117-120
9 1,5-anhydroglucitol as a marker of glycemic control in diabetes mellitus. - Its correlation with fasting plasma glucose at present or 2 weeks before -
Jichi Medical School Endocrinology and Metabolism
Ohwada N Clinical Endocrinology 1991; 39(2): 159-161
10 Serum 1,5-anhydro-D-glucitol and glycemic control in patients with non-insulin-dependent diabetes mellitus
Kyushu University Internal Medicine Umeda F Tohoku J.Exp Med 1991; 163: 93-100
11 Plasma 1,5-anhydroglucitol level in diabetes mellitus* Toyama Red Cross Hospital
Internal Medicine Hiraiwa Y Medical Journal of Toyama 1058, 22-27, 1991
12 Comparison of 1,5-Anhydroglucitol with several metabolic parameters in the treatment of Diabetes Mellitus
Saiseikai Central Hospital
Internal Medicine Suzuki Y Jpn J Med Pharm Sci. 1992; 27(3): 643-647
13 Measurement of serum 1,5-anhydroglucitol in patients with "near-normal" hyperglycemia
Shinshu University School of Medicine
Internal Medicine Komiya I J. Japan Diab. Soc. 1992; 35(5): 385-389
14 Clinical usefulness of 1,5-anhydroglucitol in Diabetes mellitus - Utility of 1,5-anhydroglucitol as a glycemic marker in initial treatment of diabetes mellitus*
Ota Nishinouchi Hospital
Diabetes Center Ota S Practice 1992; 9(2): 168-171
15 Estimation of Plasma Glucose Fluctuation with a Combination Test of Hemoglobin A1c and 1,5-Anhydroglucitol
University of Teikyo Internal Medicine Yamanouchi T Metabolism 1992; 41(8): 862-867
1 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 16 Clinical usefulness of 1,5-anhydroglucitol in assessing
treatment effect in insulin treatment for NIDDM* Toshima Hospital Internal Medicine Aiso Y Practice 1992; 9(6): 543-546
17 Clinical usefulness of the combination of HbA1c, fructosamine and 1,5-anhydro-D-glucitol as the indices of glucose control of diabetes mellitus
Saiseikai Central Hospital
Internal Medicine Hosokawa K Clinic All Round 1992; 41(9): 2536-2539
18 Clinical significance of serum 1,5-anhydro-D-glucitol measurements in diabetes mellitus
Oita Medical University
Internal Medicine Ito Y Jpn J Med Pharm Sci. 1992; 28(6): 1307-1314
19 Clinical significance of measurement of serum 1,5-anhydroglucitol in diabetes mellitus - Especially relation to nephropathy -
Hyogo College of Medicine
Clinical Pathology and Clinical Laboratories
Fujiwara K Medical Consultation and New Remedies 1993; 30(1): 125-133
20 1,5-anhydroglucitol, a novel glycemic control marker for diabetes mellitus*
Kanda Internal Medicine Clinic
Kanda M Medical Journal of Yamanashi 1992; 20:128-132
21 Evaluation of 1,5-AG determination as new marker of glycemic control
Yokufukai Geriatric Hospital
Central Clinical Laboratory
Takamatsu N Japanese Journal of Medical Technology 1993; 42(5): 961-966
22 Changes in plasma and urinary concentrations of 1,5-anhydro-D-glucitol during oral glucose tolerance test
The Institute for Diabetes Care and Research, Asahi Life Foundation
Yoshioka N J. Japan Diab. Soc. 1993; 36(11): 839-845
23 Clinical significance of serum 1,5-anhydroglucitol level in diabetic patients: A study of glucose and calcium metabolism
Osaka Prefectural General Hospital
Gastroenterology and Metabolism
Kanda T Medical Journal of Osaka Prefectural General Hospital 1993; 16(1): 16-20
24 Clinical significance of measurement of serum 1,5-anhydroglucitol*
Kinki University Internal Medicine Kishitani Y New Horizon for Medicine 1994; 26(extra I): 884-890
25 Clinical study on changes in 1,5-anhydroglucitol concentration in plasma
Teramoto Memorial Hospital
Internal Medicine Yoshikawa T Journal of Clinical Laboratory Medicine 1994; 38: 485-488
26 Variations of free non-glucose polyols in serum from patients with diabetes mellitus and their correlation with hemoglobin A1c
National Defense Medical College
Pediatrics Yoshioka S J. Natl. Def. Med. Coll 1990; 15(4): 217-223
27 Clinical usefulness of 1,5-anhydroglucitol for evaluating efficacy of treatment in non-insulin dependent diabetes mellitus. - Especially early marker reflected improvement of glycemic control - *
Kyoto Second Red Cross Hospital
Internal Medicine Okajima Y Medical Consultation & New Remedies 1994; 31(6): 1073-1078
28 Effect of aging on plasma 1,5-anhydroglucitol levels in humans and rats
Wakayama Medical College Kihoku Hospital
Internal Medicine Funasako M Diabetes Res. Clin. Pract. 1994; 25: 35-41
29 Clinical evaluation of serum 1,5AG levels in Diabetics National Kyushu Cancer Center
Gastroenterology Wakasugi H Japanese Journal of National Medical Services 1994; 48(1): 32-35
2 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 30 Significance of 1,5-anhydro-D-glucitol in diabetes mellitus
management Keio University Preventive Medicine and
Public Health Shimada N Jpn J Ind Health 1993; 36: 448-449
31 The clinical study of the diabetic marker (Centering around 1,5-AG)
Tokyo Kosei-Nenkin Hospital
Central Laboratory Yonekubo I Annual bulletin of Kosei-Nenkin Hospitals 1993; 20: 381-389
32 1,5-Anhydro-D-glucitol Evaluates daily glycemic excursions in well-controlled NIDDM
Osaka University Internal Medicine Kishimoto M Diabetes Care 1995; 18(8): 1156-1159
33 Significance of combination with acarbose in poorly controlled non-insulin dependent diabetes mellitus without obese in sulfonylurea therapy*
Osaka Prefectural General Hospital
Gastroenterology and Metabolism
Kanda T J. New Rem. & Clin. 1995; 44(10): 1699-1705
34 The significance of serum 1,5AG level in outpatients of non-insulin dependent diabetes mellitus
Tokyo Medical College
Internal Medicine Notoya Y J. Tokyo Med. Univ 1995; 53(6): 842-846
35 Plasma 1,5-anhydroglucitol as clinical marker of diabetic control
Wu D The Medical Journal of Niigata City General Hospital 1994; 15(1):13-20
36 Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control
University of Teikyo Internal Medicine Yamanouchi T THE LANCET 1996; 347: 1514-1518
37 Efficacy of combination treatment of α-glucosidase inhibitor and sulfonylurea in elder diabetic patients*
Tokyo Medical University Hachioji Medical Center
Endocrinology and Metabolism
Ohno A J. New Rem. & Clin. 1996; 45(6): 1129-1135
38 Clinical effectiveness of long-term administration of BAY g 5421 (Acarbose) on insulin-treated diabetes
Osaka University Internal Medicine Kawamori R Jpn Pharmacol Ther 1996; 24(5): 1109-1129
39 The long-term clinical trial for the evaluation of BAY g 5421 (Acarbose) combined with sulfonylurea in patients with NIDDM
Tohoku University School of Medicine
Internal Medicine Toyota T Jpn Pharmacol Ther 1996; 24(6): 1375-1392
40 Beneficial effect of an α-glucosidase inhibitor combined with conventional insulin therapy in non-insulin-dependent diabetics
Gracia Hospital Internal Medicine Watanabe N J. Japan Diab. Soc. 1996; 39(9): 679-686
41 Effect of acarbose on blood glucose profiles and plasma 1,5-anhydro-D-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapy
Nagoya University Internal Medicine Hotta N Biomedicine and Pharmacotherapy 1996; 50: 297-302
42 Predicting long-term glycemic control of post-educational type Ⅱ diabetic patients by evaluating serum 1,5-anhydroglucitol levels
University of Tsukuba Endocrinology and Metabolism
Sone H Diabetes Research & Clinical Practice 1996; 34: 83-88
43 Clinical significance of measurements of urinary and serum thrombomodulins in patients with non-insulin dependent diabetes mellitus
Dokkyo Medical University Koshigaya Hospital
Pharmaceutical Dept. Inukai T Diabetes Research & Clinical Practice 1996; 33: 99-104
44 Clinical evaluation of insulin resistance improving agent AD-4833 in patients with NIDDM controlled by only diet therapy - a double-blind, randomized, placebo-controlled test-
Yamaguchi Rosai Hospital
Kaneko T The Japanese Journal of Clinical and Experimental Medicine 1997; 74(6): 1491-1514
3 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 45 Clinical evaluation of insulin resistance improving agent
AD-4833 in NIDDM patients treated with sulfonylurea - a double-blind, randomized, placebo-controlled test-*
Yamaguchi Rosai Hospital
Kaneko T The Japanese Journal of Clinical and Experimental Medicine 1997; 74(6): 1515-1539
46 Clinical evaluation of administration of insulin resistance improving agent AD-4833 in combination with voglibose in NIDDM patients - Phase III open label study -
Yamaguchi Rosai Hospital
Kaneko T The Japanese Journal of Clinical and Experimental Medicine 1997; 74(6): 1540-1556
47 The long-term clinical trial for the evaluation of insulin resistance improving agent AD-4833 in patients with NIDDM - A late phase II study on long-term administration -*
Yamaguchi Rosai Hospital
Kaneko T The Japanese Journal of Clinical and Experimental Medicine 1997; 74(6): 1557-1588
48 The long-term clinical trial for the evaluation of insulin resistance improving agent AD-4833 in patients with NIDDM - A late phase III study on long-term administration -*
Yamaguchi Rosai Hospital
Kaneko T The Japanese Journal of Clinical and Experimental Medicine 1997; 74(6): 1589-1613
49 Pharmacokinetic study of insulin resistance improving agent AD-4833 under long-term administration - Evaluation of drug concentration in blood and efficacy for glucose -*
Hiroshima Kouseiren Hospital
Internal Medicine Takashina S The Japanese Journal of Clinical and Experimental Medicine 1997; 74(6): 1641-1626
50 Rapid improvement of serum 1,5-anhydroglucitol concentrations after administration of α-glucosidase inhibitor
Matsushita Memorial Hospital
Internal Medicine Yoshioka K Diabetes Care 1997; 20(3): 462
51 The effect of the acarbose on 1,5-anhydroglucitol level in patients with diabetes mellitus*
Mito Kyodo Hospital Metabolism and Endocrinology
Boku A Diabetes Frontier 1997; 8: 230-233
52 Study of the clinical usefulness of α-glucosidase inhibitor (voglibose) for the treatment on non-insulin-dependent diabetes
Jikei University General Internal Medicine
Funama K Jpn Pharmacol Ther 1997; 25(8): 2177-2186
53 The effects of α-glucosidase inhibitor, voglibose, on dumping syndrome and diabetes mellitus in patients after gastrectomy
Chita Khosei Hospital Internal Medicine Katagiri K J. New Remedies & Clinics 1997; 46(8): 1098-1104
54 Explanation for discrepancy between fasting plasma glucose and HbA1c*
The Institute for Diabetes Care and Research, Asahi Life Foundation
Kikuchi M Japan Medical Journal 1997; 3840: 105-106
55 Clinical significance of 1,5-anhydroglucitol in patients with diabetes mellitus - The difference among 1,5-AG , HbA1c and fructosamine -*
Gunma University Internal Medicine Shimizu M Current Therapy 1992; 10(10): 191-193
56 The usefulness of plasma 1,5-AG for a marker of glycemic control in diabetic patients
Kawasaki Medical School
Endocrinology Tsushima K Kawasaki Med J 1992; 18(1): 21-24
57 Target level of 1,5-AG in treatment with sulfonylurea* University of Teikyo Internal Medicine Yamanouchi T Japan Medical Journal 1998; 3858: 166
4 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 58 Effect of gemfibrozil on glucose tolerance in patients with
hyperlipidemia and hyperlipidemia and non-insulin-dependent diabetes mellitus
Saitama Medical School
Internal Medicine Takahashi K J. Clin. Therap. Med. 1997; 13(15): 3949-3976
59 Phase-III Study of a novel hypoglycemic agent AY4166, on NIDDM patients in Japan (2): Placebo-controlled multicenter double-blind study
Siga University of Medical Science
Shigeta Y Clinical Pharmacology and Therapy 1997; 7(5): 729-754
60 Usefulness of combination therapy with sulfonylurea and α-glucosidase inhibitor (voglibose) in non-insulin dependent diabetes mellitus: Effect of reducing the dose of sulfonylurea
Urayasu Hospital of Juntendo University School of Medicine
Internal Medicine Iijima T Jpn Phamacol Ther 1997; 25(3): 841-849
61 Effect of voglibose on glycemic excursions insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients
Sasebo Chuou Hospital
Internal Medicine Matsumoto K Diabetes Care 1998; 21(2): 256-260
62 Different effect of acarbose and voglibose on serum 1,5-anhydroglucitol concentrations
Ayabe Municipal Hospital
Internal Medicine Sakane N Diabetes Care 1998; 21(3): 465
63 Response to Sakane et al. Matsushita Memorial Hospital
Internal Medicine Yoshioka K Diabetes Care 1998; 21(3): 465-466
64 α-glucosidase inhibitor: a therapeutic use in diabetes mellitus and the other disorders in glucose metabolism
Fukuoka University Clinical Laboratory Ono J Clinic All-Round 1998; 47(6): 1862-1867
65 Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up
University of Teikyo Internal Medicine Yamanouchi T Diabetes Care 1998; 21(4): 619-624
66 Acarbose Yamashiro Hospital Internal Medicine Nakano K Japanese Journal of Clinical Medicine 1997; 55(extra): 120-124
67 Combination therapy with sulfonylurea and α-glucosidase inhibitor
Urayasu Hospital of Juntendo University School of Medicine
Internal Medicine Iijima T Japanese Journal of Clinical Medicine 1997; 55(extra): 186-191
68 Case report: A GAD positive patient with diabetes mellitus received diet therapy*
Oomiya Medical Center Jichi Medical University
General Medicine Namai K Diabetes Frontier 1997; 8: 235-243
69 A diabetic case with hemoglobin J-Meerut and low HbA1c levels
Tokai University School of Medicine
Nephrology and Metabolism
Yagame M Internal Medicine 1997; 36(5): 351-356
70 Pioglitazone(AD-4833) ameliorates insulin resistance in patients with NIDDM
Osaka University Internal Medicine Yamazaki M Tohoku J.Exp.Med. 1997; 183: 173-183
71 Insulin-like growth factors-Insulin-like growth factor binding protein axis and diabetic control in insulin-dependent diabetes mellitus
Keio University School of Medicine
Pediatrics Hasegawa T Endocrine J. 1998; 45(Suppl): S129-S131
5 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 72 Effect of α-glucosidase inhibitor on plasma 1,5-
anhydroglucitol level* Kurihara Clinic Kurihara Y Practice 1998; 15(1): 81-85
73 Case report: A patient with continuous high glucagon level hospitalized for ketoacidosis*
Ebara Hospital Internal Medicine Soeda H Diabetes Frontier 1998; 9(6): 779-786
74 Case report: A difficult case with maintaining good glycemic control for a professional reason
Kanto Chuou Hospital Metabolism Hayashi M Diabetes Frontier 1999; 10(1): 135-141
75 Insulin-sensitizing agent University of Teikyo Internal Medicine Yamanouchi T Japanese Journal of Clinical Medicine 1999; 57(3): 675-680
76 Discrepancy between HbA1c and 1,5-AG* University of Teikyo Internal Medicine Yamanouchi T Doctor Salon 1999; 43(7): 553-557 77 Plasma 1,5-anhydroglucitol compared to glycosylated
hemoglobin as clinical markers for diabetes in first-time patients
Matsuyama Red Cross Hospital
Internal Medicine Yamauchi Y Ehime Medical Journal 1999; 18(4): 540-543
78 Serum 1.5-anhydro-D-glucitol as a new clinical marker for glucose metabolism in type2 diabetes
Shanghai Medical University
Diabetes Research Department
Hongli SHI Chinese Medical Journal 1999; 112(6): 571-573,1999
79 Utility of voglibose long term combined therapy in non-insulin dependent diabetic patients with little effective of sulfonylurea
Ehime Prefectural Central Hospital
Internal Medicine Fujii Y Japanese Journal of Medicine and Pharmaceutical Science 1999; 42(1): 121-129
80 Effect of "Rensen granule" on disorders of glucose metabolism*
Isogo Chuou Hospital Healthcare Tsuchida T Medical Consultation & New Remedies 1999; 36(6): 481-484
81 Effect of restricted physical activity on glycemic control in a type-1 diabetic patients with the mitochondrial DNA 3234 (A to G) mutation
Nagaoka Red Cross Hospital
Medicine and Diabetes Center
Kamoi K J. Japan Diab. Soc. 2000; 43(6): 477-481
82 Comparison of clinical effect between acarbose and voglibose in type 2 diabetes - crossover study - *
Yamashiro Hospital Internal Medicine Nakano K Practice 2000; 17(1): 73-79
83 Glycemic control state of diabetes outpatients* Jyuzen General Hospital
Central Clinical Laboratory
Shiomi A The Ehime Journal of Medical Technology 1997; 16: 57-59
84 Oral glucose tolerance test in sixty gastrectomized subjects with reference to oxyhyperglycemia
Institute of Industrial and Ecological Sciences
Health Policy and Management
Kaji H J. Japan Diab. Soc. 2001; 44(7): 549-554
85 Effect of Nateglinide on uncontrolled type 2 diabetes treated with diet*
Tokyo Medical Center Internal Medicine Koyama K J. New Rem. & Clin. 2001; 50(4): 419-423
86 Dosage selection of sulfonylurea in changing from glibenclimide to Glimepiride*
Teikyo University Internal Medicine Sekine N J. New Rem. & Clin. 2001; 50(7): 717-724
87 Usefulness of data analysis system for diabetic control "Medisafe data vision" *
Juntendo University School of Medicine
Endocrinology and Metabolism
Fujita A Practice 2001; 18(1): 74-80
6 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 88 Post-load glucose measurements in oral glucose
tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance
Teikyo University Internal Medicine Yamanouchi T Clinical Science 2001; 101: 227-233
89 A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia
Tokyo Medical and Dental University
Internal Medicine Tanaka A Clinica Chimica Acta 2001; 312: 41-47
90 Effect of Chinese herbal medicine (Ginseng Radix Rubra and Kidney-Qi Pill ) - Retrospective study using FPG, HbA1c and 1,5-AG as glycemic marker*
Nishiarai Hospital Internal Medicine Kim M J. New Rem. & Clin. 2001; 50(11),1147-1153
91 Educational hospitalization programs for diabetes patients by Sapporo General Hospital; Effectiveness of short-term physical exercise for type 2 diabetes mellitus
Sapporo City General Hospital
Rehabilitation Shimizu K The Hokkaido Journal of Physical Therapy 2001; 18: 33-39
92 Growth hormone replacement therapy and glucose metabolism*
Fukuoka City Pediatric Hospital
Infection Center Kohno H Annual report of Foundation for Growth Science 2001; 24: 219-221
93 1,5-anhydroglucitol as clinical marker of diabetic control Shizuoka General Hospital
Clinical Laboratory Amemiya N Shizuoka J Med 2001; 16(1), 67-73
94 The effect of high carbohydrate diet on glucose tolerance in patients with type 2 diabetes mellitus
Yamanashi Medical University
Internal Medicine Komiyama N Diabetes Res Clin Pract 2002; 57(3): 163- 170
95 Clinical heterogeneity in elderly patients with diabetes mellitus
Osaka University Aging Fujisawa T Jpn J Geriat 2002; 39(4): 390-392
96 Attempt of at-home medical care using measurement device for urinary glucose, "Well You" and FAX communications system*
Li Internal Medicine Clinic
Li G Practice 2002; 19(1): 89-93
97 Serum 1,5-Anhydroglucitol (GlycoMark TM): A short-term glycemic marker
University of North Carolina School of Medicine
Endocrinology Buse JB Diabetes Technology & Therapeutics 2003; 5(3): 355-363
98 Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia
Teikyo University Internal Medicine Sekino N Diabetes Obes Metab 2003; 5(3): 145-149
99 Changing HbA1c and 1,5-anhydro-D-glucitol in diabetic patients
Osaka Red Cross Hospital
Clinical Laboratory Yamada M Japanese Journal of Medicine and Pharmaceutical Science 2002; 47(3): 475-479
100 Glycated albumin (GA) is highly useful as a glycemic control marker compared with HbA1c under insulin treatment diabetes mellitus (DM) patients
Funayama Clinic Funayama H J. Jap Diab. Soc. 2003; 46(5): 375-379
101 Changing serum urinary acid in type 2 diabetic patients under inpatient management
Tokyo Medical University Hachioji Medical Center
Endocrinology and Metabolism
Ohno A Prog. Med. 2004; 24: 755-759
7 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 102 Circulating 1,5-Anhydroglucitol levels in adult patients
with diabetes reflect longitudinal changes of glycemia Washington University School of Medicine
McGill JB Diabetes Care 2004; 27(8): 1859-1865
103 Diabetic renal hypouricemia Teikyo University Internal Medicine Yamanouchi T Kidney and Dialysis 2003; 55(2): 353-356
104 Effect of hot spring water drinking on glucose metabolism
Hokkaido University Health Administration Center
Ohtsuka Y Journal of the Japanese Society of Balneology, Climatology and Physical Medicine 2003; 66(4): 227-230
105 Postprandial plasma fructose level is associated with retinopathy in patients with type 2 diabetes
Teikyo University Internal Medicine Kawasaki T Metabolism 2004; 53(5): 583-588
106 Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes
Nerima General Hospital
Internal Medicine Yanagawa T Metabolism 2004; 53(3): 353-357
107 Different effects of two α-glucosidase inhibitor, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level
Juntendo University School of Medicine
Internal Medicine Watanabe K J Diabetes Complications 2004; 18(3): 183-186
108 Case Report; Delayed increase of serum pancreatic enzymes with onset of a fulminant type 1 diabetes mellitus*
Wakayama Medical University
Internal Medicine Nakao T J. Japan Diab. Soc. 2005; 48(8): 627-631
109 Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes
Teikyo University Internal Medicine Yamanouchi T Diabetic Medicine 2005; 22(8): 980-985
110 Voglibose Nagoya University Graduate School of Medicine
Internal Medicine Nakamura J Japanese Journal of Clinical Medicine 2005; 63(extra): 457-461
111 The application of plasma 1,5-anhydro-D-glucitol for monitoring type 2 diabetic patients
Poznan Univ. Pharmacology Dworacka M Disease markers 2005; 21(3): 127-132
112 Evaluation of 1,5-AG in diabetic patients treated with α-glucosidase inhibitor*
Kawarazaki Hospital Shirahata M Practice 2005; 22(6): 689-694
113 Comparison of effect on glycemic control between Novorapid 30 mix and Novorin 30R*
Okayama Medical Center
Internal Medicine and Metabolism
Hida K Prog.Med. 2005; 25(8): 2216-2220
114 Factors related to bone metabolism in type 2 diabetes* Itabashi Central General Hospital
Internal Medicine Sasamoto K The Japanese Journal of Clinical and Experimental Medicine 2004; 81(9): 1559-1565
115 Endocrinology and metabolic diseases -especially diabetes mellitus -
Hokkaido University Health Administration Center
Ohtsuka Y Journal of the Japanese Society of Balneology, Climatology and Physical Medicine 2002; 66(1): 21-22,
116 Efficacy and safety of once daily gliclazide (20mg/day) compared with Nateglinide
Juntendo University School of Medicine
Endocrinology and Metabolism
Miwa S Endocrine J 2004; 51(4): 393-398
8 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 117 Serum uric acid concentrations in type 2 diabetes: its
significant relationship to serum 1,5-anhydroglucitol concentrations
Aichi Medical University
Gotho M Endocrine regulations 2005; 39(4): 119-125
118 Clinical efficacy of miglitol in type 2 Japanese diabetics with diet alone - Phase II dose response study -
Tohoku Kosei Nenkin Hospital
Internal Medicine Goto Y Jpn Pharmacol Ther 2005; 33(11): 1099-1111
119 Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea
Poznan University of Medical Science
Pharmacology Dworacka M Int J Clin Pharmacol Ther 2006; 44(1): 14-21
120 Effects of Kurozu Moromi Powder and Kurozu concentrated liquid on carbohydrate metabolism
Sakamoto Brewing Co., Ltd.
Nagano M Jpn Pharmacol Ther 2006; 34(2): 199-206
121 Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus
Piazzale Stefani University Hospital
Bonora E Diabetologia 2006; 49: 846-854
122 1,5-anhydroglucitol and postprandial hyperglycemia as measured by a continuous glucose monitoring system in patients with inadequately controlled diabetes mellitus
Buse JB Endocrine Practice 2005; 11(Suppl 1): Abstract#912
123 Optimizing glimepiride dose in patients with type 2 diabetes by titration from 3 mg/day to 6 mg/day
Teikyo University Internal Medicine Igarashi K Prog.Med. 2006; 26(9): 2257-2262
124 Short term intensive insulin therapy improves insulin secretion significantly in type 2 diabetic patients
National Hospital Organization Kyushu Medical Center
Metabolism and Endocrinology
Ogo A Fukuoka Acta Med. 2006; 97(9): 277-284
125 The association between glycoxidation and chronic or acute hyperglycaemia in type2 diabetic patients with retinopathy
Poznan University Medical Science
Pharmacology Dworacka M Int J Diabetes & Metabolism 2006; 14(1): 27-31
126 Relationship between 1,5-anhydroglucitol and result of carotid artery ultrasound in elderly patients -cross sectional study in non-diabetic patients - *
Nippon Medical School
geriatrics Ohba K Summary Control Report 2006
127 Pro-Atherogenic alterations in T-Lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients
Pozan University Medical Science
Pharmacology Dworacka M Circulation Journal 2007; 71: 962-967
128 Evaluation of glucose lowering effects of mitiglinide in type 2 diabetes patients
Yokohama City University
Graduate School of Clinical Research
Tanaka S Jpn Pharmacol Ther2007; 35(supplement): S5-S21
129 Hyperglycemia and diabetic renal change in a model of polyvinyl alcohol bioartificial pancreas transplantation
Kyoto University Organ Reconstruction and Biomaterials
Sakata N Pancreas 2007; 34(4): 458-465
130 Voglibose improves postprandial glycemic state , reduces oxidative stress and prevent progression of arteriosclerosis*
Kyoto Medical Center Sato T Journal of Metabolic Syndrome 2007; 3(1): 62-69
131 Comparison of glimepiride and mitiglinide in drug-naïve type 2 diabetic patients
Jichi Medical University
Endocrinology and Metabolism
Nagasaka S Jpn J Diabet Mast Clin 2007; 5(4): 395-400
9 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 132 Miglitol increases the adiponectin level and decrease
urinary albumin excretion in patients with type2 diabetes mellitus
Jiyugaoka Medical Clinic
Internal Medicine Yokoyama H Metabolism Clinical and Experimental 2007; 56: 1458-1463
133 Investigation of rapid-acting insulin analogue (insulin aspart) for CSII
Kurume University School of Medicine
Endocrinology Imamura Y J. Japan Diab. Soc. 2008; 51(1): 1-7
134 Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions?
Novo Nordisk Inc., Moses AC Diabetic Medicine 2008; 25(2): 200-205
135 Type 1 diabetes mellitus (adult)* Saitama Medical Center
Internal Medicine Maruyama T The Japanese Journal of Clinical Nutrition 2000; 97(4): 499-504
136 Effects of mitiglinide on glucose and lipid metabolism in poorly-controlled type 2 diabetic patients with dyslipidemia
Nippon Medical School
Internal Medicine Watanabe K Therapeutic Research 2008; 29(5): 811-819
137 Current strategies for evaluating, monitoring, and treating type 2 diabetes mellitus
Chino Medical Group Diabetes and headache Intervention Center
Unger J Am J Med. 2008; 121(6,suppl): S3-S8, 2008
138 Relationship between 1,5-anhydroglucitol and development of diabetic retinopathy
Fujisawa Municipal Hospital
Internal Medicine Hoshino K J. Japan Diab. Soc. 2004; 47(11): 845-850
139 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes
University of North Carolina School of Medicine
Endocrinology Dungan KM Diabetes Care 2006; 29(6): 1214-1219
140 Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1α maturity-onset diabetes of the young
Jagiellonian University
Metabolic Diseases Skupien J Diabetes Care 2008; 31(8): 1496-1501
141 Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients
University Hospital Bern
Endocrinology Stettler C Diabetes Care 2008; 31(8): 1534-1535
142 Replacement of voglibose by miglitol resulted in further improvement of glycemic control in patients with type 2 diabetes
Miura Medical Clinic Miura Y Prog.Med. 2008; 28(9): 2241-2244
143 Evaluation of self monitoring of blood ketones by an electrochemical sensor in type 1 diabetes patients
Matsushita Memorial Hospital
Central Clinical Laboratory
Nakajima Y Japanese Journal of Medical Technology 2008; 57(5): 823-827
144 Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients
Yokohama City University
Endocrinology and Metabolism
Aoki K Diabetes, Obesity and metabolism 2008; 10(10): 970-972
145 Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in Type 2 diabetic patients
Isala Clinics Clinical Chemistry Schindhelm RK Diabetes Care 2008; 31(11): e89
146 Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in Type 2 diabetic patients
University of Bern Endocrinology Stettler C Diabetes Care 2008; 31(11): e90
10 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 147 Relationship of 1,5-anhydroglucitol (1,5AG) to other
baseline characteristics in insulin-Naïve type 2 diabetes (T2D) patients in the DURABLE trial
Ohio State University Dungan KM ADA 68th Annual Scientific Sessions, June 6-10, 2008
148 Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naïve type2 diabetic patients
Kitasato Institute Hospital
Diabetes Center Masuda H Diabetes Obes Metab 2008; 10(12): 1261-1265
149 1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decrease insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes
Sungkyunkwan University School of Medicine
Internal Medicine Won JC Diab. Res. Clin. Pract 2009; 84(1): 51-57
150 Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
Banyu Pharmaceutical Co.,Ltd.
Nonaka K Diabetes Res Clin Pract 2008; 79(2): 291-298
151 Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion
Tulane University Health Sciences Thethi TK Journal of Diabetes and Its Complications 2010; 24: 73-78
152 Clinical significance of miglitol, new alpha-glucosidase inhibitor, to impaired glucose tolerance
Kurume University School of Medicine
Endocrinology Sato S Therapeutic Research 2009; 30(4): 517-523
153 Racial and ethnic differences in mean plasma glucose, Hemoglobin A1c, and 1,5-Anhydroglucitol in over 2000 patients with type 2 diabetes
University of Michigan
Internal Medicine and Epidemiology
Herman WH J Clin Endocrinol Metab 2009; 94(5): 1689-1694
154 Taspoglutide, a once-weekly human GlP-1 analogue, reduces postprandial glucose (PPG) levels and provides long-term glucose control in ZDF rats
Sebokova E Diabetes 2009; 69th ADA
155 1,5anhydroglucitol concentrations and measures of glucose control and glucose variability in T1DM and T2DM patients
Kuenen JC Diabetes 2009; 69th ADA
156 Utility of 1,5-anhydroglucitol(1,5-AG) in assessing glycemia among youth and adults with type 1 diabetes (T1D)
Mehta SN Diabetes 2009; 69th ADA
157 Unfavorable BNP change with the use of Thiazolidinediones in therapy of mild type 2 diabetes patients
Shirabe S Diabetes 2009; 69th ADA
158 Glycemia indicators influenced on 1,5-anhydroglucitol and hemoglobin A1c among non-diabetic subjects
Nomura K Diabetes 2009; 69th ADA
159 Relationship between long-range correlated glucose fluctuation and indices of glucose control humans
Ogata H Diabetes 2009; 69th ADA
160 Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring(CGM)
St. Marianna University School of Medicine
Metabolism and Endocrinology
Suwa T Endocr.J. 2010; 57(2): 135-140
11 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 161 Relationship between long-range correlated glucose
fluctuation and indices of glucose control using continuous glucose monitoring
University of Tokyo Ogata H J.Physiol.Sci 2009; 59(Supplement1): 333
162 Pleiotropic effects of mitiglinide in type 2 diabetes mellitus
Hyogo College of Medicine
Diabetes and Metabolism
Konya H Journal of international medical research 2009; 37(6): 1904-1912
163 The use of 1,5anhydroglucitol level as a clinical test to differentiate subtypes of diabetes
University of Oxford Diabetes Research Laboratories
Owen KR Diabetologia 2009; 52(Suppl1): S105
164 Postprandial glucose levels and long-term glucose control are improved with taspoglutide, a human once-weekly GLP-1 analogue, in an animal model of type 2 diabetes
F.Hoffmann-La Roche AG
Sebokava E Diabetologia 2009; 52(Suppl1): S308
165 BNP elevation following 12-week pioglitazone treatment in patients with type 2 diabetes
Shinkawabashi Hospital
Shirabe S Diabetologia 2009; 52(Suppl1): S335
166 The influence of needle length on glycaemic control and injection-related complaints in obese diabetes subjects
University Medical Center
Endocrinology Kreugel G Diabetologia 2009; 52(Suppl1): S377
167 Urinary myoinositol index: a new and better marker for postprandial hyperglycaemia
Toho University School of Medicine
Diabetes, Metabolism and Endocrinology
Miyagi M Diabetologia 2009; 52(Suppl1): S401
168 Is 1,5AnhydroGlucitol associated with malondialdehyde a marker for oxidase stress?
VU University Medical Center
Diabetes Center Kuenen J Diabetologia 2009; 52(Suppl1): S500-S501
169 Clinical significance of 3 times-daily administration of Humalog Mix 50 (50% insulin lispro and 50% insulin lispro protamine suspension injection) *
Toho University School of Medicine
Diabetes and Endocrinology Center
Kawana H Prog.Med. 2009; 29(11): 2669-2672
170 Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtype of diabetes
University of Oxford Diabetes Research Laboratories
Pal A Diabetes 2010; Care 33(2): 252-257
171 Association between diabetes-related distress and postprandial hyperglycemia in patients with diabetes
University South Caroline School of Medicine
Medicine Coleman SR Canadian Journal of Diabetes 2009; 33(3): 238
172 Serum uric acid levels positively correlated with serum 1,5-anhydroglucitol levels in patients with type 2 diabetes mellitus
Kinki Central Hospital Health Care Center Koga M Official Journal of Japan Society of Ningen Dock 2010; 24(5): 40-44
173 Evaluation of 1,5-anhydroglucitol as a marker for glucose variability in patients with type 2 diabetes mellitus
Kim MJ Diabetes 2010; (70th ADA)
174 1,5-anhydroglucitol, but not fructosamine or HbA1c, predicted glycemic remission in patients of newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy
Liu L Diabetes 2010; (70th ADA)
175 Utility of 1,5-anhydroglucitol (1,5AG) for guiding insulin therapy in type 2 diabetes (T2D) patients (Pts) with suboptimal control on oral antidiabetic agents
Dungan KM Diabetes 2010; (70th ADA)
12 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 176 Evaluation of relationship between postprandial glucose
level and progression of atherosclerosis in normal glucose-tolerant patients with hypertension of dyslipidemia by using carotid ultrasound variables and serum 1,5-anhydroglucitol (1,5-AG)
Watanabe K Diabetes 2010; (70th ADA)
177 Black-white differences in hemoglobin A1c (HbA1c) and other glycemic markers
Selvin E Diabetes 2010; (70th ADA)
178 1,5-anhydroglucitol level is a useful marker reflects the early response for miglitol therapy in type 2 diabetic patients
Kanda J Diabetes 2010; (70th ADA)
179 A novel new glycemic variability metric Schwartz FL Diabetes 2010; (70th ADA) 180 The investigation of daily profile of blood glucose
analyzed with CGMS in well-controlled with Type 1 diabetes between with and without unaware severe hypoglycemia
Miura J Diabetes 2010; (70th ADA)
181 Clinical use of 1,5-AG (Glycomark) in isle transplantation Gracia MIDO Diabetes 2010; (70th ADA) 182 Dose-ranging efficacy of sitagliptin, a dipeptidyl
peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
Tokyo Women's Medical University
Diabetes Center Iwamoto Y Endocr J 2010; 57(5): 383-394
183 Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial
Tokyo Women's Medical University
Diabetes Center Iwamoto Y Diabetes Obes Metab 2010; 12, 613-622
184 1,5-anhydroglucitol levels are associated with postprandial hyperglycemia and coronary artery disease in non-diabetic subjects
Yokohama City University Medical Center
Otsuka F Circulation Journal 2010; 74(Suppl.1): 300
185 Lower levels of serum 1,5-anhydroglucitol (1,5-AG) are associated with acute coronary syndrome (ACS)
Disaster Medical Center
Cardiovascular Medicine Kato R Circulation Journal 2010; 74(Suppl.1): 481-482
186 Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70
Sakura Hospital Medical Center, Toho University
Center of Diabetes Ohira M Metabolism Clinical and Experimental 2010; 60: 78-85
187 Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes
Kinki Central Hospital Internal Medicine Koga M Clinical Biochemistry 2010; 43: 1265-1267
188 Single administration of α-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease
Juntendo University School of Medicine
Cardiovascular Medicine Hiki M Circulation Journal 2010; 74: 1471-1478
189 Exenatide added to insulin glargine-treated patients with type 2 diabetes provided excellent fasting and postprandial control with weight loss and no increased risk of hypoglycaemia
International Diabetes Center
Bergenstal RM Diabetologia 2010; 53(Suppl1): S37
13 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 190 Efficacy of miglitol on postprandial glucose control
assessed by continuous glucose monitoring Jichi Medical University
Endocrinology and Metabolism
Nagasaka S Diabetologia 2010; 53(Suppl1): S362
191 The DURABLE Trial: comparing durability of lispro mix 25 vs. glargine
University Medical Center Groningen
Endocrinology Wolffenbuttel BHR
Diabetologia 2010; 53(Suppl1): S383
192 1,5-Anhydroglucitol as a marker of short term glucose variability in well-controlled type 2 diabetes mellitus
Kyung Hee University Hospital
Endocrinology and Metabolism
Lee YJ Diabetologia 2010; 53(Suppl1): S399
193 An information-motivation-behavioral skills analysis in frequent testers
University of Western Ontario
Psychology Kohut T Diabetologia 2010; 53(Suppl1): S419
194 Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat
F. Hoffmann-La Roche AG
Sebokova E Diabetes, Obesity and Metabolism 2010; 12: 674-682
195 Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests
National Center for Global Health and Medicine
Diabetes and Metabolic Medicine
Goto M Endocr J 2011; 58(1): 13-17
196 The efficacy on 1,5-anhydroglucitol (1,5AG) as a marker of postprandial hyperglycemia by DPP-4 inhibitor sitagliptin
Mejiro Medical Clinic Hisano N Japanese Journal of Medicine and Pharmaceutical Science 2010; 64(4): 589-592
197 Long-term treatment of miglitol ameliorate dyslipidemia and fatty liver in diabetic outpatients
Misaki Naika Clinic Kuribayasi N Therapeutic Research 2010; 31(11): 1617-1623, 2010
198 Case report; A fulminant type 1 diabetes mellitus developed during hospitalization for impaired consciousness*
Tokyo Medical and Dental University
Molecular Endocrinology and Metabolism
Miyake A J. Japan Diab. Soc. 2011; 54(2): 107-111
199 Racial difference in glycemic markers: A cross-sectional analysis of community-based data
Johns Hopkins Bloomberg School of Public Health
Epidemiology and Clinical Research
Selvin E Ann Intern Med 2011; 154(5): 303-309
200 Lower levels of serum 1,5-anhydroglucitol are associated with non-diabetic patients with acute coronary syndrome
災害医療センター Cardiovascular Medicine Ito J JACC 57 2011; (Supplement1): E937
201 Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: An 11-year population-based cohort study in Japan, the Suita study
National Cerebral and Cardiovascular Center
Preventive Cardiology Watanabe M Atherosclerosis 2011; 216: 477-483
202 Nontraditional markers of glycemia - Associations with microvascular conditions
Johns Hopkins Bloomberg School of Public Health
Epidemiology Selvin E Diabetes Care 2011; 34: 960-967
203 Randomized trial on the influence of the length of two insulin pen needle on glycemic control and patient preference in obese patients with diabetes
University Medical Center Groningen
Endocrinology Kreugel G Diabetes Technology & Therapeutics 2011; 13(7): 737-741
14 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 204 Treatment with the α-glucosidase inhibitor miglitol from
the preonset stage in Otsuka long-evans Tokushima fatty rats improves glycemic control and reduces the expression of inflammatory cytokine gene in peripheral leukocytes
University of Shizuoka
Laboratory of Nutrition Physiology
Mochizuki K Metabolism 2011; 60(11): 1560-1565
205 Relationship between postprandial hyperglycemia and renal tubular function in patients without diabetes
Ouchi M American Diabetes Association 2011; (71st)
206 Is 1,5Anhydroglucitol(Glycomark) a clinically useful test in type 1 diabetes?
Duran-Valdez E American Diabetes Association 2011; (71st)
207 Relationships between glycemia, oxidative stress and inflammation in type 1 diabetic patients using insulin pumps
Jenkins AJ American Diabetes Association 2011; (71st)
208 Clinical Evaluation of DPP-4 inhibitor vildagliptin* Ayame Clinic Ayame H J. New Rem. & Clin. 2011; 60(8): 1569-1575
209 Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus
Hyogo College of Medicine
Diabetes and Metabolism
Katsuno T J. Diabetes Invest. 2011; 2(3): 204-209
210 Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study
Kansai Electric Power Hospital
Seino Y Current medical research and opinion 2011; 27(9): 1781-1792
211 The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data
Changhua Chistian Hospital
Endocrinology and Metabolism
Shi-Dou Lin Journal of Diabetes and Its Complications 2011; 25, 332-338
212 Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70
Toho University Medical Center Sakura Hospital
Center of Diabetes, Endocrine and Metabolism
Ohira M Journal of Diabetes 2011: 3(SUPPL1): 267
213 Plasma 1,5-anhydroglucitol levels as marker of postprandial hyperglycemia are correlated with severity of left ventricular dysfunction in patients with acute myocardial infarction
University of Fukui Ishida K European heart journal 32(Suppl.1), 1060 ,2011
214 Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus
Seoul National University College of Medicine
Internal Medicine Kim MJ Acta Diabetol 2013; 50: 505-510
215 Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus
Hyogo College of Medicine
Diabetes and Metabolism
Nagai E Endocr J. 2011; 58(10): 869-877
216 A patients with acute lymphoblastic leukaemia presenting with an extremely high level (21.0%) of HbA1c
Kitasato University School of Medicine
Hematology Suzuki Y Ann Clin Biochem. 2011; 48: 474-477
15 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 217 Close relationship between serum 1,5-anhydroglucitol
levels and serum uric acid levels in subjects with normal glucose tolerance
Kinki Central Hospital Internal Medicine Koga M Gout and Nucleic Acid Metabolism 2011; 35(1): 9-17
218 Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study
Monteagle Medical Center
Bohannon N Diabetes Technol Ther 2011; 13(10): 1031-1037
219 Does measurement of serum 1,5-anhydroglucitol (1,5-AG) level be able to predict the presence of coronary plaque?
Nagoya Heart Center Murase S J.Am.Coll.Cardiol 2011; 58(20): B169
220 Effect of intensive antidiabetic therapy on sleep-disordered breathing in patients hospitalized for poorly controlled type 2 diabetes mellitus
Osaka University Metabolic Medicine Kashine S The Japan Atherosclerosis Society Annual Meeting 2011; 43rd: 244
221 Retrospective cohort study on cardiovascular event in diabetic patients
National Cerebral and Cardiovascular Center
Preventive Cardiology Miyamoto Y General report in 2010 2011; 84-85
222 Do α-glucosidase inhibition have potential benefits beyond glucose-lowering effect?*
Jichi Medical University
Endocrinology and Metabolism
Nagasaka S Jpn J Diabet Mast Clin 2011; 9(4): 403-407
223 Effect of sitagliptin on postprandial hyperglycemia* KKR Sapporo Medical Center Tonan Hospital
Diabetes and Endocrinology
Hida Y Practice 2011; 28(3): 320-323
224 Effect of periodontal disease treatment on glycemic control in diabetic patients*
Gifu Prefectural General Medical Center
Diabetes and Endocrinology
Yoshino K Prog.Med. 2011; 31(10): 2463-2467
225 Selective contribution of waist circumference reduction on the improvement of sleep-disordered breathing in patients hospitalized with type 2 diabetes mellitus
Osaka University Metabolic Medicine Kashine S Internal Medicine 2011; 50: 1895- 1903
226 Effect of 3-month repeated administration of Miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease
Hyogo Prefectural Awaji Hospital
Cardiovascular Medicine Emoto T The American Journal of Cardiology 2012; 109(1): 42-46
227 Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients
Chinese People's Liberation Army General Hospital
Endocrinology Sun J Chinese medical Journal 2011; 124(22): 3641-3645
228 Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome
Nottingham Medical School
Galazis N Eur J Obstet Gynecol Reprod Biol. 2012; 160(2): 121-130
229 Plasma 1,5anhydroglucitol levels, a measure of short-term glycaemia: Assay assessment and lower levels in diabetic vs. non-diabetic subjects
University of Melbourne
Medicine Januszewski AS Diabetes Res Clin Pract 2012; 95: e17-e19
16 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 230 A pilot study of the efficacy of miglitol and sitagliptin for
type 2 diabetes with a continuous glucose monitoring system and incretin-related markers
National Center for Global Health and Medicine
Diabetes and Metabolic Medicine
Kishimoto M Cardiovascular Diabetology 2011; 10: 115-123
231 Metabolomic profiling of patients with new-onset type 1 diabetes: an insight into early metabolic changes
Connolly Hospital Endocrinology Tisdall AR Ir. J. Med. Sci. 2011; 180: S501-S502
232 Effect of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia; an open-label, randomized, case-control, crossover study
Nippon Medical School
Internal Medicine Suzuki T Journal of Diabetes and its Complications 2011; 26: 34-39
233 Medium-term repeated administration of miglitol improves vascular endothelial dysfunction in diabetic patients with coronary artery diseases - evaluation using Flow-Mediated Dilatation
Hyogo Prefectural Awaji Hospital
Internal Medicine Emoto T Circulation 2011; 124: A9929
234 Characterizing blood glucose variability using new metrics with continuous glucose monitoring data
Ohio University Electrical Engineering and Computer Science
Marling CR Journal of Diabetes Science and Technology 2011; 5(4): 871-878
235 Relationship between serum 1,5-AG levels and macrovascular diseases (coronary artery disease, stroke) in Suita cohort study
Keio University Preventive Medicine and Public Health
Okamura T General report in 2010 2011:171-175
236 Effect of Sitagliptin on the result of 75g OGTT* Minamikosigaya Kenshinkai Clinic
Shuto H J. Saitama M. S. 2011; 46(1): 139-142
237 Effect of DPP-4 inhibitor (sitagliptin) on glucose metabolism and heart and renal function in type 2 diabetic patients*
Hiramitsu Heart Clinic Hiramitsu N Prog.Med. 2012; 32(2): 337-344
238 Does examination of 1,5-anhydroglucitol (1,5-AG) be able to predict a coronary artery plaque?
Nagoya Heart Center Cardiovascular Medicine Cardiovascular Medicine
Murase S Annual Meeting of the Cardiovascular Intervention and Therapeutics 2011; 20th: 445
239 The lack of long-range negative correlations in glucose dynamics is associated with worse glucose control in patients with diabetes mellitus
The University of Tokyo
Educational Physiology Laboratory
Ogata H Metabolism Clinical and Experimental 2012; 61: 1041-1050
240 A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycemia excursions as measured by Continuous Glucose Monitoring System among type 2 diabetes in Chinese population
Zhongda Hospital Endocrinology Wang Y Diabetes Metab Res Rev. 2012; 28: 357-362
241 Serum 1,5-anhydroglucitol is low in gastrectomized men Kinki Central Hospital Internal Medicine Murai J Acta Diabetol 2014; 51(2): 337-338
242 Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in type 2 diabetes
Kangbuk Samsung Hospital
Endocrinology and Metabolism
Kim WJ Diabet Med. 2012; 29(9): 1184-1190
17 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 243 Potential for use of 1,5-anhydroglucitol when initiating
insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs
Ohio State University Medical Center
Dungan KM Diabetes Res Clin Pract 96, e66-e69, 2012
244 Effects of sex and age on serum 1,5-anhydroglucitol in nondiabetic subjects
Nippon Medical School
Internal Medicine Ouchi M Exp Clin Endocrinol Diabetes 2012; 120: 288-295
245 Clinical significance of insulin glulisine - Comparison with 3 insulin analog -*
Osaka City General Hospital
Metabolism and Endocrinology
Hosoi M J. New Rem. & Clin. 2012; 61(3): 439-445
246 Effect of vildagliptin on daily blood glucose fluctuation in type 2 diabetes*
Taneda Medical Clinic Taneda Y J. New Rem. & Clin. 2012; 61(2): 222-229
247 Clinical effect of DPP-4 inhibitor vildagliptin in type 2 diabetes*
Taneda Medical Clinic Taneda Y J. New Rem. & Clin. 2012; 61(2): 231-237
248 Lower levels of serum 1,5-anhydroglucitol in well controlled diabetic patients with acute coronary syndrome
Tokyo Disaster Medical Center
Cardiovascular Medicine Ito J Circulation Journal 2012; 76(Suppl.1): I-1434
249 Impact of 1,5-anhydro-D-glucitol on restenosis and TLR in patients underwent percutaneous coronary intervention
Tokyo Disaster Medical Center
Cardiovascular Medicine Hirasawa K Circulation Journal 2012; 76(Suppl.1): I-2322
250 Membrane type 1-matrix metalloproteinase is a predictor of coronary plaque in patients with postprandial hyperglycemia
University of Fukui Cardiovasular Medicine Uzui H Circulation Journal 2012; 76(Suppl.1): I-2323
251 The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes
Kanagawa Physicians Association
The Study Group of the Diabetes Committee
Maeda H Diabetes Res Clin Pract 2012; 95: e20-e22
252 Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
Kyoto University Diabetes and Clinical Nutrition
Inagaki N Journal of Diabetes Investigation 2011; 2(6): 448-456
253 Alternative markers of glycemia and risk of diabetes in the atherosclerosis risk in communities(ARIC) study
Juraschec SP Diabetes 2012; 61(SUPPL1): A7
254 Vascular health in type 1 diabetes: CSII vs. MDI Januszewski AS Diabetes 2012; 61(SUPPL1): A228 255 The investigation of risk factor for the hypoglycemia
unawareness in patients with type 1 diabetes using CGMS
Miura J Diabetes 2012; 61(SUPPL1): A554
256 The efficacy and safety of the combination usage of mitiglinide and depeptidyl-peptidase-4 inhibitor sitagliptin
Togo M Diabetes 2012; 61(SUPPL1): A622
257 Pilot study of caffeine abstinence for control of chronic glucose in type 2 diabetes
Duke University Medical Center
Psychiatry and Behavioral Sciences
Lane JD Journal of caffeine research 2012; 2(1): 45-47
258 Effect of GLP-1 analogue on continuous glucose monitoring*
Tokyo Jikei University School of Medicine Kashiwa Hospital
Diabetes, Metabolism and Endocrinology
Mori Y The Journal of Therapy 2012; 94(5): 1009-1011
18 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 259 Serum 1,5-anhydro-D-glucitol levels predict first-ever
cardiovascular disease: An 11-year population-based cohort study in Japan, the Suita study
National Cerebral and Cardiovascular Center
Preventive Cardiology Watanabe M Current Diabetology 2012; 3(3): 164-165
260 Clinical efficacy of miglitol as add-on treatments in type 2 diabetes - Changing of glycemic marker and microalbuminuria*
Komatsu Clinic Komatsu K Diabetes Frontier 2012; 23(3): 351-354
261 Effect of increasing DPP-4 inhibitor vildagliptin on glycemic control*
Iketani Clinic Iketani T J. New Rem. & Clin. 2012; 61(9): 1764-1768
262 Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s)
Kyoto University Diabetes and Clinical Nutrition
Inagaki N Clinical Therapeutics 2012; 34(9): 1892-1908
263 Increased 1,5-Anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy
Sun Yat-Sen University
Endocrinology Liu L Diabetes Technology & Therapeutics 2012; 14(9): 756-761
264 Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
Jikei University School of Medicine
Diabetes, Metabolism and Endocrinology
Sakamoto M Cardiovasc Diabetol 2012; 11: 92
265 Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: A randomized comparable study
The University of Tokushima Graduate School of Health Biosciences
Cardio-Diabetes Medicine
Shimabukuro M
Int J Cardiol 2013; 167(5): 2108-2113
266 Improved endothelial cell function and inflammation after replacement of insulin by liraglutide in combination with metformin and sulfonylurea in type 2 diabetic patients
Imamura Bun-in Hospital
Diabetes Kamada T Diabetologia 2012; 55(Suppl1): S321
267 Dipeptidyl peptidase-4 inhibitor (sitagliptin) improves insulin sensitivity and atherosclerosis-related biomarkers in patients with type 2 diabetes
Asahi General Hospital
Diabetes and Metabolic Disease
Yamane T Diabetologia 2012; 55(Suppl1): S323
268 Combination therapy with low dose glimepiride and sitagliptin is effective for poorly controlled Japanese patients with type 2 diabetes
Shinshu University School of Medicine
Aging Medicine Ishii H Diabetologia 2012; 55(Suppl1): S343
269 Alternative markers of hyperglycemia and risk of diabetes Johns Hopkins School of Medicine
Medicine Juraschek SP Diabetes Care 2012; 35(11): 2265-2270
270 Association of alternative markers of glycemia with hemoglobin A1c and fasting glucose
Johns Hopkins School of Medicine
Epidemiology and Clinical Research
Juraschek SP Clinical Chemistry 2012; 58(12): 1648-1655
271 Comparing multiple measures of glycemia: How to transition from biomarker to diagnostic test ?
University of Cincinnati College of Medicine
Medicine Cohen RM Clinical Chemistry 2012; 58(12): 1615-1617
19 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 272 Relationship between nontraditional and standard
markers of glycemia Johns Hopkins Univ Juraschek SP Circulation 125, AMP039, 2012
273 Serum 1,5-anhydro-D-glucitol(1,5AG) is associated with endothelial dysfunction and coronary plaque vulnerability in diabetes patients with coronary artery diseases
Hyogo Prefectural Awaji Hospital
Cardiovascular Medicine Cardiovascular Medicine
Emoto T Cardiovascular Intervention and Therapeutics 2012; 4(Supplement2): 629
274 Efficacy and safety of switching from insulin glargine to insulin detemir in Japanese type 1 diabetes
Saitama Medical School
Endocrinology and Diabetes
Kurihara S Therapeutic 2012; Research 33(9): 1389-1396
275 Urinary myoinositol index: A new and better marker for postmeal hyperglycemia
Toho University School of Medicine
Diabetes, Metabolism and Endocrinology
Miyagi M Showa Univ J Med 2012; 24(1): 33-41
276 Effect of DPP-4 inhibitor on insulin withdrawal in diabetic patients*
Tama General Medical Center
Internal Medicine Sakurada M Clinical Study Report (2011) 2013:360-363
277 Dose-ranging study of anagliptin in Japanese patients with type 2 diabetes - A multi-center, randomized, placebo-controlled, double-blind, parallel-group study -
Kawasaki Medical School
Diabetes, Endocrinology and Metabolism
Kaku K Jpn Pharmacol Ther 2012; 40(11): 973-984
278 Effectiveness of the glucagon test in estimating islet function for liraglutide treatment in a lean diabetes patient with impaired insulin response to glucose
Gifu University Diabetes and Endocrinology
Iizuka K Diabetol Int 2012; 3: 103-108
279 Clinical efficacy and safety of insulin glulisine in poorly controlled patients with diabetes*
Hiroshima Kyoritsu Hospital
Diabetes Morishita N J. New Rem & Clin 2013; 62(2): 193-199
280 A case of hypoglycemia induced by exenatide, under continuous glucose monitoring in a patients with type 2 diabetes
Kashiwado Hospital Internal Medicine Tokuyama Y J. Japan Diab. Soc. 2013; 56(2): 81-86
281 A multicenter, PhaseIII Evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes
Takeda Pharmaceutical Co.,Ltd.
Pharmacovigilance Hiroi S Diabetes Technology & Therapeutics 2013; 15(2): 158-165
282 An anti-inflammatory sterol decreases obesity-related inflammation-induced insulin resistance and metabolic dysregulation
Harbor Therapeutics, Inc.
Reading CL Mediators of Inflammation 2013; Article ID 814989: 16
283 Relationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease
Nippon Medical School
Internal Medicine Watanabe K BMC Cardiovascular Disorders 2013; 13: 11
284 Comparison of the anti-atherogenic and anti-metabolic effects between miglitol and nateglinide in diabetic patients with coronary artery disease
Hyogo Prefectural Awaji Hospital
Sawada T American Journal of Cardiology 2013; 111(7): 32B
20 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 285 Effect of 3 times daily insulin aspart 70 in poorly
controlled type 2 diabetes treated with twice daily insulin mix*
Hirosaki University Endocrinology and Metabolism
Matsuhashi Y Prog. Med. 2013; 33(3): 585-588
286 Clinical study of a fixed-dosed mitiglinide/voglibose combination in patients with type 2 diabetes mellitus - Clinical assessment of glycemic markers, HbA1c, glycated albumin and 1,5-anhydroglucitol -
MVCCT Study Group of the Shibuya Medical Association
Hiyoshi T Therapeutic Research 2013; 34(3): 379-390
287 Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study
Japanese Red Cross Medical Center
Kojima Y World J Diabetes 2013; 4(1): 8-13
288 Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
The University of Tokyo
Graduated School of Medicine
Kadowaki T Journal of Diabetes Investigation 2013; 4(2): 174-181
289 Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus
Kyung Hee University School of Medicine
Endocrinology and Metabolism
Chon S Diabetes Technology & Therapeutics 2013; 15(6): 455-460
290 Increased glycemic variability at the onset and during progression of type 2 diabetes - Commentary
Biomedical Informatics Consultants LLC
Rodbard D Diabetes Technology & Therapeutics 2013; 15(6): 445-447
291 The use of 1.5-anhydroglucitol for monitoring glycemic control in islet transplant recipients
Diabetes Research Institute
Peixoto EML Cell Transplant 2014; 23(10): 1213-1219
292 Comparison of the effect of ultra-rapid insulin in intensive insulin therapy*
Kanazawa Red Cross Hospital
Diabetes and Kidney Center
Hamaguchi E J. New Rem. & Clin. 2013; 62(7): 1273-1281
293 Epidemiology of Diabetes and cardiovascular disease* National Cerebral and Cardiovascular Center
Preventive Cardiology Watanabe M Prevention of Arteriosclerosis 2013; 12(1): 12-17
294 Plasma 1,5-anhydroglucitol levels on admission can predict the ventricular function at 1-month after an acute myocardial infarction: A novel predictor
University of Fukui School of Medical Sciences
Cardiovascular Medicine Koike M Circulation Journal 2013; 77(Suppl.I): I-2024
295 Preprocedual lower levels of serum 1,5-anhydroglucitol are associated with restenosis after percutaneous coronary intervention
Tokyo Disaster Medical Center
Cardiology Cardiovascular Medicine
Ito J Circulation Journal 2013; 77(Suppl.I): I-2616
296 1,5-anhydroglucitol is a stronger predictor of coronary artery disease than hemoglobin A1c
National Center for Global Health and Medicine
Cardiovascular Ikeda N Circulation Journal 2013; 77(Suppl.I): I-2617
297 Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy
Kumamoto University Metabolic Medicine Shimoda S Endocr J. 2013; 60(10): 1207-1214
21 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 298 Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor,
on glucose parameters, the activity of the advanced glycation end product-receptor for advanced glycation end product axis, and albuminuria in Japanese type 2 diabetes
University of Miyazaki
Internal Medicine Sakata K Diabetes Metab Res Rev 2013; 29: 624-630
299 Dipeptidyl peptidase-4 inhibitors improve glycaemic control in latent autoimmune diabetes in adults (LADA) patients insufficiently controlled despite insulin therapy
Gunma University、Schoold of Medicine
Clinical Laboratory Araki O 49th EASD 2013; No.884
300 Two prandial insulin approaches for achieving adequate glycaemic control in patients not at goal HbA1c on basal insulin plus oral agents alone: the AUTONOMY study
University of California San Diego
Veterans Affairs Medical Center
Edelman S 49th EASD 2013; No.1024
301 Switching from intensive insulin therapy to basal supported oral therapy with sitagliptin or glimepiride*
Toyota Kouseiren Hospital
Internal Medicine Katoh D J. New Rem. & Clin. 2013; 62(9): 1561-1568
302 Efficacy and safety of glycemic control in type 2 diabetes patients when switched to mitiglinide/voglibose fixed-dose combination therapy*
Keio University School of Medicine
Nephrology, Endocrinology and Metabolism
Saisyo Y J. New Rem. & Clin. 2013; 62(9): 1569-1575
303 Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes
St. Marianna University School of Medicine
Metabolism and Endocrinology
Ohta A Expert Opin. Pharmacother 2013; 14(17): 2315-2322
304 Comparison of effects of α-glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease
Himeji Brain and Heart Center
Cardiovascular Medicine Sawada T Circ J. 2014; 78(1): 248-255
305 Effect of Canagliflozin, a sodium glucose co-transporter 2 inhibitor, on measurement of serum 1,5-anhydroglucitol
Janssen Research & Development
Balis DA J Diabetes. 2014; 6(4): 378-380
306 Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism
Nippon Medical School
Endocrinology and Metabolism
Asai A Journal of diabetes investigation 2011; 2(4): 318-323
307 Ameliorating effects of miglitol on postprandial hyperglycemia and triglyceride/HDL ratio are associated with beneficial impact on atherosclerosis in diabetic patients with coronary artery disease
Hyogo Prefectural Awaji Medical Care Center
Terashita D European heart journal 2013; 34: 414-415
308 Relationship between preprocedual serum 1,5-anhydroglucitol concentrations and restenosis after implantation of drug-eluting stent
Disaster Medical Center
Cardiology Cardiovascular Medicine
Ito J European heart journal 2013; 34: 786
309 Efficacy and safety of switching from intensive insulin therapy to insulin glulisine*
Toyota Kouseiren Hospital
Endocrinology and Metabolism
Katoh D J. New Rem. & Clin 2014; 63(1): 71-77
310 Clinical efficacy of sitagliptin in Japanese type 2 diabetes* Watanabe Clinic Watanabe G J. New Rem. & Clin 2014; 63(2): 192-199
22 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 311 1,5-anhydroglucitol in saliva is a noninvasive marker of
short-term glycemic control Weill Cornell Medical College
Physiology and Biophysics
Mook-Kanamori DO
J Clin Endocrinol 2014; Metab 99(3): E479-E483
312 Long-term effects of mitiglinide in Japanese diabetics inadequately controlled with DPP-4 inhibitor or biguanide monotherapy
Kawasaki Medical School
Diabetes, Endocrinology and Metabolism
Kaku K Diabetes Ther 2014; 5(1): 97-111
313 Thresholds of various glycemic measures for diagnosing diabetes based on prevalence of retinopathy in community-dwelling Japanese subjects: the Hisayama Study
Kyushu University Environmental Medicine Mukai N Cardiovascular Diabetology 2014; 13:45
314 Circulating CD3+56+ cell subset in pre-diabetes Poznan University Medical Science
Pharmacology Dworacka M Exp Clin Endocrinol Diabetes 2014; 122(2): 65-70
315 Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin
Osaka University Graduate School of Medicine
Metabolic Medicine Takahara M Endocr J. 2014; 61(5): 447-456
316 The prognostic value of 1,5-anhydroglucitol Johns Hopkins University
Selvin E Circulation 2014; 129: SUPPL.1
317 Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk
Saitama Medical Center, Jichi Medical University
Cardiovascular Medicine Fujiwara T Heart and Vessels 2015; 30(4): 469-476
318 Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides
Mie Chuo Medical Center
Internal Medicine Tanaka T J Diabetes Invest 2014; 5(2): 199-205
319 Successful treatment with liraglutide in a diabetic patients with widely fluctuating blood glucose levels due to the formation of insulin antibodies
Akita Red Cross Hospital
Metabolism Kudo H J. Japan Diab. Soc. 2014; 57(3): 175-180
320 Decreased plasma 1,5-anhydroglucitol in diabetic patients
Akanuma Y Diabetes 1981; 30(Suppl 1): 124A
321 1.5-anhydro-D-glucitol: a novel marker of glucose excursions
Karol Marcinkowski University of Medical Sciences
Pharmacology Dworacka M International Journal of Clinical Practice 2002; Supplement 129: 40-44
322 A patients with variant hemoglobin diagnosed based on abnormal pattern between the s-A1c and A0 peaks on routine laboratory HbA1c measurement using HPLC
Aichi-Gakuin University
Internal Medicine Naruse K J. Japan Diab. Soc. 57(2): 118-123
323 Effectiveness of miglitol combined with various types of insulin therapy for reducing the daily glycemic fluctuation on Japanese type 2 diabetic patients
Toho University School of Medicine
Diabetes, Metabolism and Endocrinology
Hirose T Ther Res 2013; 34(12): 1503-1511
324 What is the determinant for circulating endothelial progenitor cells in patients with coronary artery disease and type 2 diabetes mellitus?
University of Fukui Cardiovascular Medicine Cardiovascular Medicine
Morishita T Circulation Journal 2014; 78(Suppl.1): I-2683
23 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 325 The relationship between postprandial blood glucose and
coronary plaque stability in stable angina patients; Optical coherence tomography analysis
Urasoe General Hospital
Cardiovascular Medicine Uehara H Circulation Journal 2014; 78(Suppl.1): I-1775
326 Predictive values of 1,5-anhydro-d-glucitol and hemoglobin A1c for prevalence of coronary artery disease in non-diabetic population
National Center for Global Health and Medicine
Cardiovascular Medicine Ikeda N Circulation Journal 2014; 78(Suppl.1): I-1360
327 Clinical efficacy and safety of insulin glulisine* Hiroshima Kyoritsu Hospital
Diabetes Morishita N J. New Rem. & Clin. 2014; 63(3): 345-350
328 Effect of combination therapy with sitagliptin in type 2 diabetes with insulin therapy*
Tama General Medical Center
Internal Medicine Satoh F Clinical Study Report (hospital management in Tokyo, 2012) 2014: 545-549
329 Relationship between average and variability of glucose and glycemic markers in measurement of CGM*
Jichi Medical University
Endocrinology and Metabolism
Nagasaka S Research Report of Daiwa Securities Health Foundation 2014; 37: 18-23
330 1,5-AG as an index of glycemic variability and its application to therapy evaluation
Kashiwado Hospital Internal Medicine Tokuyama Y J. Japan Diab. Soc. 2014; 57(4): 227-234
331 1,5-anhydro-D-glucitol predicts coronary artery disease prevalence and complexity
National Center for Global Health and Medicine
Cardiovascular Medicine Ikeda N Journal of Cardiology 2014; 64(4): 297-301
332 Association of reduced levels of serum 1,5-anhydro-D-glucitol with carotid atherosclerosis in patients with type 2 diabetes
Itoigawa General Hospital
Sato T Journal of Diabetes and Its Complications 2014; 28(3): 348-352
333 Exploratory trial of intranasal administration of Glucagon-Like Peptide-1 in Japanese patients with type 2 diabetes
University of Miyazaki
Neurology,Respirology, Endocrinology and Metabolism
Ueno H Diabetes Care 2014; 37(7): 2024-2027
334 Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients
The University of Shizuoka
Laboratory of Nutritional Physiology
Imai C Metabolism 2014; 63(6): 746-753
335 Statins in low doses reduce VEGF and bFGF serum levels in patients with type 2 diabetes mellitus
Poznan University of Medical Science
Pharmacology Dworacka M Pharmacology 2014; 93: 32-38
336 1,5-anhydro-D-glucitol predicts prevalence of coronary artery disease even in non-diabetic adults
National Center for Global Health and Medicine
Cardiovascular Medicine Ikeda N Journal of the American College of Cardiology 2014; 63(Issue 12): A1331
337 Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes
University of Occupation and Environmental Health
Internal Medicine Torimoto K Cardiovascular Diabetology 2014; 13: 99
338 Effect of repaglinide, administered two of three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus
Yokohama City University Graduate School of Medicine
Endocrinology and Metabolism
Kamiyama H Journal of International Medical Research 2014; 42(5): 1150-1160
24 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 339 Effects of intake of puffed wx ae double mutant brown
rice on human blood glucose and lipid levels Osaka Prefecture University
Rehabilitation Horino S J Life Sci Res 2011; 9: 7-11
340 The effects of combination therapy with miglitol and sitagliptin in patients with type 2 diabetes who showed an inadequate response to monotherapy with either agent
Nakakinen Clinic Osonoi K Medical Consultation & New Remedies 2011; 48(5): 471-482
341 Addition of sitagliptin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes on glinides monotherapy
Tajima N Diabetes 2014; 63: A268 (74th ADA)
342 The relationship among alternative markers of glycemia and A1C, 2-hr PG, and continuous glucose monitoring in obese adolescents
Chan LC Diabetes 2014; 63: A314-A315 (74th ADA)
343 A prospective metabonomics analysis reveals new pathways involved in T2D development
Arredouani A Diabetes 2014; 63: A414 (74th ADA)
344 1,5-anhydroglucitol and methylglyoxal - new post-mortem marker for glucose metabolism disorders?
Institute of Forensic Medicine
Hess C Rechtsmedizin 2011; 21(4): 406-407
345 The soluble isoform of the receptor for advanced glycation end products (esRAGE) as a biomarker for long-term glycemic control in type 2 diabetes
Federal University of Parana
Anghebem-Oliveria MI
Clin Chem Lab Med 2014; 52(Special Suppl.): S639
346 Effects of standard dose of vildagliptin vs sitagliptin on blood glucose fluctuations evaluated by long-term self-monitoring blood glucose (SMBG)
Hokkaido University Medine II Kimachi K Diabetologia 2014; 57(Suppl 1): S379
347 Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients
Ajinomoto Co., Inc. Institute for innovation Nakamura H Nutr Diabetes 2014; 4: e133 (1-8)
348 Association of 1,5-anhydroglucitol with diabetes and microvascular conditions
Johns Hopkins Bloomberg School of Public Health
Epidemiology Selvin E Clin Chem. 2014; 60(11): 1409-18
349 Moving beyond mean glycemia: 1,5-anhydroglucitol and microvascular complications of diabetes
Harvard Medical School
Cardiovascular Division Lawler PR Clin Chem. 2014; 60(11): 1359-1361
350 Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes
St. Marianna University School of Medicine
Metabolism and Endocrinology
Asai S Endocr J 2014; 61(12): 1213-1220
351 Effect of sitagliptin on glycemic control in type 2 diabetes treated with low dose of glimepiride*
Iwamizawa Municipal General Hospital
Internal Medicine Yoshimura H Diabetes Frontier 2013; 24(6): 747-751
352 The efficacy of sitagliptin on glycemic control in type 2 diabetes with treatment of vildagliptin
Hotaruno Central Clinic of Internal Medicine
Uchida D Medical Consultation & New Remedies 2014; 51(5): 519-522
353 The efficacy of combination therapy with α-glucosidase inhibitor plus DPP-4 inhibitor*
Hotaruno Central Clinic of Internal Medicine
Uchida D Ther Res 2014; 35(6): 615-620
25 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 354 Strong correlation between glycaemic variability and
total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control
Dong-A University Medical Center
Endocrinology and Metabolism
Suh S Diabetes & Metabolism 2014; 40(4): 272-277
355 Clinical significance of measurement of 1,5-anhydroglucitol in patients with coronary artery disease and acute coronary syndrome
Juntendo University School of Medicine
Cardiovascular Medicine Sai E Circulation Journal 2014; 78(Suppl.I): OE-154
356 Efficacy of alogliptin on glucose parameters, the activity of the advanced glycation end product- receptor for advanced glycation end product axis, and albuminuria in uncontrolled type 2 diabetes
University of Miyazaki
Sakata K The Journal of Clinical Hypertension 2013; 15(suppl.1): A45
357 Prescription and quality of diabetes care provided by specialists and general physicians in Japan - An analysis of insurance claim and health checkup data -
SANYO Electric Group Health Insurance
The Health Care Center Hidaka H J. Japan Diab. Soc. 2014; 57(10): 774-782
358 Comparative associations of diabetes risk factor with five measures of hyperglycemia
The Welch Center for Prevention
Epidemiology Poon AK BMJ Open Diabetes Res Care. 2014; Apr 8;2(1) [Epub ahead of print]
359 Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus
Kawasaki Medical School
Diabetes, Endocrinology and Metabolism
Tatsumi F Diabetes Research & Clinical Practice 2013; 101(1): 35-44
360 Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes
Kawasaki Medical School
Diabetes, Endocrinology and Metabolism
Kaku K Diabetes Care 2013; 36(2): 245-250
361 Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus
Yuri Ono Clinic Diabetes Ono Y Expert Opin. Pharmacother 2013; 14(4): 361-370
362 Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
Ashiya Municipal Hospital
Internal Medicine Konya H Diabetes, Metabolic Syndrome and Obesity: Target and Therapy 2013; 6: 317-325
363 Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
Jikei University School of Medicine
Metabolic Diseases Tajima N Journal of Diabetes Investigation 2013; 4(6): 595-604
364 Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy
The University of Tokyo
Metabolic Diseases Kadowaki T Diabetol Int 2013; 4: 160-172
365 'Patient-centered care' for complex patients with type 2 diabetes mellitus - Analysis of two cases
University of Massachusetts Boston
Nursing and Health Science
Hackel JM Clinical Medicine Insights: Endocrinology and Diabetes 2013; 6: 47-61
366 Effects of alogliptin in chronic kidney disease patients with type 2 diabetes
Nippon Medical School Musashikosugi Hospital
Nephrology Sakai Y Internal Medicine 2014; 53: 195- 203
26 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 367 SYR-472, a novel once-weekly dipeptidyl peptidase-4
(DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2 randomized, double-blind, placebo-controlled trial
Kyoto University Graduated School of Medicine
Diabetes Inagaki N Lancet Diabetes Endocrinol 2014; 2: 125-132
368 Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomized trial
VU University Medical Center
Diabetes Center Diamant M Lancet Diabetes Endocrinol 2014; 2: 464-473
369 The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus
Yuri Ono Clinic Diabetes Ono Y Expert Opin. Pharmacother. 2014; 15(3): 311-324
370 Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase
Kawasaki Medical School
Diabetes, Endocrinology and Metabolism
Kaku K Expert Opin. Pharmacother. 2014; 15(15): 2121-2130
371 Initiation and gradual intensification of premixed insulin lispro therapy versus basal ±mealtime insulin in patients with type 2 diabetes eating light breakfast
Second University of Naples
Geriatrics and Metabolic Diseases
Giugliano D Diabetes Care 2014; 37(2): 372-380
372 AUTONOMY: The first randomized trail comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes
University of California
Medicine Edelman SV Diabetes Care 2014; 37(8): 2132-2140
373 Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes
VU University Medical Center
Diabetes Center Diamant M Diabetes Care 2014; 37(10): 2763-2773
374 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial
Chiba University Graduate School of Medicine
Clinical Cell Biology and Medicine
Kobayashi K Diabetes, Obesity and Metabolism 2014; 16(8): 761-765
375 The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial
Mountain Diabetes and Endocrine Center
Lane W Diabetes, Obesity and Metabolism 2014; 16: 827-832
376 Using miglitol at 30 min before meal is effective in hyperinsulinemic hypoglycemia after a total gastrectomy
Yokohama-City University
Endocrinology and Metabolism
Shirakawa J Endocrine Journal 2014; 61(11): 1115-1123
377 Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
Ashiya Municipal Hospital
Internal Medicine Konya H Therapeutics and Clinical Risk Management 2014; 10: 547-558
378 Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes - Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study -
Kumamoto University Cardiovascular Medicine Ogawa H Circulation Journal 2014; 78: 2512-2515
27 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 379 Comparison of the administration of teneligliptin every
day versus every other day in Japanese patients with type 2 diabetes: A randomized non-inferior test
Yokohama-City University
Endocrinology and Metabolism
Kamiko K Journal of Clinical Pharmacology 2015; 55(2): 144-151
380 Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
Kanazawa University Graduated School of Medical Sciences
Disease Control and Homeostasis
Takeshita Y J Diabetes Invest 2015; 6(2): 192-200
381 Association of retrospective markers of glycemia and the use of continuous glucose monitoring in white adults with type 2 diabetes mellitus - a preliminary report
Jagiellonian University
Diagnostics Solnica B Clin Chem Lab Med 2015; 53(1): e15-e17
382 Salivary protein glycosylation as a noninvasive biomarker for assessment of glycemia
Nizam's Institute of Medical Sciences
Rao PV Journal of Diabetes Science and Technology 2015; 9(1): 97-104
383 Predictive value of 1,5-anhydroglucitol for prevalence of coronary artery disease in non-diabetic adults
National Center for Global Health and Medicine 国立国際医療研究センター
Caridiology Cardiovascular Medicine
Ikeda N European Heart Journal 2014; 35(Suppl1): 399
384 A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study
Osaka University Metabolic Medicine Hibuse T Cardiovascular Diabetology 2014; 13: 96
385 Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: A phase I, single-center, open-label, randomized study
Peking Union Medical College Hospital
Clinical Pharmacology Chen X Clinical Therapeutics 2014; 36(8): 1196-1210
386 The rs10885122 polymorphism of the adrenoceptor alpha 2A (ADRA2A) gene in Euro-Brazilians with type 2 diabetes mellitus
Federal University of Parana
Pharmaceutical Sciences Welter M Arch Endocrinol Metab. 2015; 59: 29-33
387 GlycA is novel marker of inflammation among non-critically ill hospitalized patients with type 2 diabetes
The Ohio State University
Endocrinology, Diabetes and Metabolism
Dungan KM Inflammation 2015; Jan 15 [Epub ahead of print]
388 Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Endocrinology and Metabolism
Ma X Cardiovascular Diabetology 2015; 14: 16
389 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes
Uijeongbu St. Mary's Hospital
Endocrinology and Metabolism
Seok H Diabetes Metab J. 2015; 39(2): 164-170
390 Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study
Kyoto University Graduated School of Medicine
Diabetes, Endocrinology and Nutrition
Inagaki N Lancet. Diabetes & Endocrinology 2015; 3(3): 191-197
28 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 391 Racial differences in hyperglycemia: Comparative value of
traditional and nontraditional glycemic markers Johns Hopkins Bloomberg Sch of Public Health
Epidemiology Parrinello CM Circulation 2015; 131: AP296
392 Glycemic excursions and cognitive function in older adults with diabetes
Johns Hopkins University
Rawlings A Circulation 2015; 131: AP339
393 Association of cerebral white matter lesions with cognitive function and mood in Japanese elderly people: a population-based study
Tottori University Neurology Yamawaki M Brain Behav. 2015; 5(3): 8
394 Two non-diabetic cases of variant hemoglobin treated with oral hypoglycemic agents due to spurious HbA1c elevation
Osaka General Medical center
Diabetes and Metabolism
Shimizu S J. Japan Diab. Soc. 2015; 58(2): 121-127
395 Two patients with low HbA1c levels due to subclinical hemolysis
Kawanishi City Hospital
Internal Medicine Nakamura Y J. Japan Diab. Soc. 2015; 58(2): 128-135
396 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with newly diagnosed type 2 diabetes mellitus
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Endocrinology and Metabolism
Ma X Diabetes Technol Ther. 2015; 17(5): 320-326
397 Association of serum 1,5-anhydro-D-glucitol with coronary artery atherosclerosis and epicardial adipose tissue volume assessed by computed tomography in non -diabetic patients
Kurekyosai Hospital Cardiology Cardiovascular Medicine
Kunita E 79th Annual Sceintific Meeting of JCS 2015; OJ-021
398 Impact of serum 1,5-anhydro-d-glucitol value on prediction of major adverse cardiac and cerebrovascular events
National Center for Global Health and Medicine
Cardiology Cardiovascular Medicine
Ikeda N 79th Annual Sceintific Meeting of JCS 2015; OJ-050
399 Efficacy of dipeptidyl peptidase-4 inhibitor for cardiac function in diabetic patients with ischemic heart disease
Nihon University School of Medicine
Cardiology Cardiovascular Medicine
Kitano D 79th Annual Sceintific Meeting of JCS 2015; OJ-053
400 Serum levels of 1,5-anhydroglucitol predict in-stent restenosis after drug-eluting stent implantation
Disaster Medical Center
Cardiology Cardiovascular Medicine
Yamamoto T 79th Annual Sceintific Meeting of JCS 2015; PE-357
401 Efficacy of dipeptidyl peptidase-4 inhibitor for cardiac function in diabetic patients with ischemic heart disease
Nihon University School of Medicine
Cardiology Cardiovascular Medicine
Kitano D JACC 2015; 65(10): A1417
402 Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention
Jichi Medical University
Cardiovascular Medicine Fujiwara T Heart Vessels 2016; 31: 855-862
403 Efficacy of switching from premix analog insulin twice daily injection to insulin glargine once daily injection with sitagliptin
Minamiakatsuka Clinic
Internal Medicine Takahashi H Diabetol Int 2015; 6: 33-38
29 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 404 1,5-anhydro-D-glucitol can reflect hypoglycemia in
patients with well controlled type 2 diabetes Seoul National University Hospital
Internal Medicine Kim MK Diabetes Research and Clinical Practice 2014; 106(SUPPL. 1): S90-S91
405 Low levels of C-peptide have clinical significance for established type 1 diabetes
Faustman DL Diabetes 2015; 64(SUPPL.1): A71-A72
406 Risk prediction of major complications in persons with diabetes
Parrinello CM Diabetes 2015; 64(SUPPL.1): A72
407 Glycemic variability correlates with 1.5-anhydroglucitol (1.5-AHG) but not with markers of oxidation, inflammation, and endothelial function: Baseline characteristics of the CAROLINA CGM substudy
Mazze RS Diabetes 2015; 64 (SUPPL.1): A246
408 Insulin mid mixture lispro mix50 (LM50) showed better glycemic control than low mixture lispro mix 25 (LM25) as starter insulin in Chinese patients with type 2 diabetes mellitus (T2DM): A subgroup analysis of CLASSIFY study
Su Q American Diabetes Association 2015; (75th)
409 The effect of fasting status on 23 cardiometablic biomarkers in 96,000 subjects
Varvel SA American Diabetes Association 2015; (75th)
410 Short-term total variability in nontraditional biomarkers of hyperglycemia in older adults
Parrinello CM Diabetes 2015; 64(SUPPL.1): A433-434
411 Point-of-Care salivary protein glycosylation test for assessment of short-term glycemia
Roberts CT Diabetes 2015; 64(SUPPL.1): A636
412 Capsule commentary on Radin, Pitfalls in hemoglobin A1c measurement: When results may be misleading
San Francisco VA Medical Center
Feingold KR J Gen Intern Med 2013; 29(2): 363
413 Increased circulating RANTES in type 2 diabetes Poznan University of Medical Sciences
Pharmacology Dworacka M Eur. Cytokine Netw. 2014; 25(3): 46-51
414 Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy
Dokkyo Medical University
Endocrinology and Metabolism
Tanaka S Diabetes Technology & Therapeutics 2014; 16(12):840-845
415 Switching from ultra-rapid insulin therapy to mitiglinide in patients with Basal bolus treatment*
Akita Red Cross Hospital
Metabolism Goto T Diabetes Frontier 2015; 26(2): 229-232
416 HOMA-IR values are associated with glycemic control in Japanese subjects without diabetes or obesity: the KOBE study
Foundation for Biomedical Research and Innovation
Hirata T J Epidemiol 2015; 25(6): 407-414
417 Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study
Kyushu University Center for Cohort Studies
Mukai N Cardiovascular Diabetology 2015; 14: 84
418 Low levels of C-peptide have clinical significance for established Type 1 diabetes
Harvard Medical School
Immunobiology Laboratory
Kuhtreiber WM
Diabet Med. 2015; 32(10): 1346-1353
30 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 419 Discrimination of sulfonylureas -How to use gliclazide and
glimepiride properly ? - National Hospital Organization Kagoshima Medical Center
Diabetes and Endocrine Medicine
Ijuin T Prog. Med. 2015; 35(7): 1217-1224
420 Effects of liraglutide monotherapy on beta cell function and pancreatic enzymes compared with metformin in Japanese overweight/obese patients with type 2 diabetes mellitus: A subpopulation analysis of the KIND-LM randomized trial
Keio University School of Medicine
Internal Medicine Tanaka K Clin Drug Investig 2015; 35(10): 675-684
421 Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study
Kanazawa University Graduated School of Medical Sciences
Disease Control and Homeostasis
Takeshita Y BMJ Open Diabetes Res Care. 2015; 3: e000122
422 Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes
Kitasato University School of Medicine
Cardiovascular Medicine Hashikata T Heart Vessels 2016; 31: 1303-1310
423 Effect of postprandial hyperglycemia on coronary flow reserve in patients with impaired glucose tolerance and type 2 diabetes mellitus
University of Fukui Cardiovascular Medicine Ikeda H Diabetes & Vascular Disease Research 2015; 12(6): 405-410
424 Association of 1,5-anhydroglucitol with cardiovascular disease and mortality
Johns Hopkins Bloomberg School of Public Health
Epidemiology and the Welch Center for Prevention
Selvin E Diabetes 2016; 65(1): 201-208
425 Case study: type 2 diabetes treated with DPP-4 inhibitor in combination with mitiglinide/voglibose combination tablets*
Kyorin University Hospital
Internal Medicine Sumitani Y Calm 2015; 2(2): 14-15
426 Is it possible to switch from intensive insulin therapy to therapy with glargine and sitagliptin or glimepiride in type 2 diabetes? *
Toyota Kousei Hospital
Internal Medicine Kato D Journal of New Remedies and Clinic 2015; 64(6): 635-643
427 Impact of serum 1,5-anhydro-d-glucitol value on prediction of major adverse cardiac and cerebrovascular events
National Center for Global Health and Medicine
CardiologyCardiovascular Medicine
Ikeda N European Heart Journal 2015; 36(SUPPL.1): 18
428 Impact of low serum levels 1,5-anhydroglucitol on cardiovascular events in patients after first-time elective percutaneous coronary intervention
Juntendo University School of Medicine
Cardiology Cardiovascular Medicine
Takahashi S European Heart Journal 2015; 36(SUPPL.1): 641
429 Total short-term variability in biomarkers of hyperglycemia in older adults
Johns Hopkins Bloomberg School of Public Health
Epidemiology and Welch Center for Prevention
Parrinello CM Clinical Chemistry 2015; 61(12): 1540-1541
430 Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol
Jefferson University Hospitals
Pathology Fortuna D Clinical Chimica Acta 2016; 452: 138-141
31 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 431 Ability of 1,5-anhydro-D-glucitol values to predict
coronary artery disease in a non-diabetic population National Center for Global Health and Medicine
Cardiovascular Medicine Ikeda N Int Heart J 2015; 56(6): 587-591
432 Racial differences in glycaemic marker levels among individuals without diabetes: the coronary artery risk development in young adults study
University of Alabama
Cardiology Carson AP Diabetologia 2015; 58(Suppl 1): S178
433 Glycaemic variability correlates with 1.5-AHG but not with markers of oxidation, inflammation and endothelial function: baseline results of the CAROLINAⓇ CGM substudy
International Diabetes Center
Mazze R Diabetologia 2015; 58(Suppl 1): S564
434 Plasma metabolomic profiles in association with type 2 diabetes risk and prevalence in Chinese adults
Vanderbilt Epidemiology Center
Epidemiology Yu D Metabolomics 2016; 12: 3
435 Racial differences in and prognostic value of biomarkers of hyperglycemia
Johns Hopkins University
Epidemiology and the Welch Center for Prevention
Parrinello CM Diabetes Care 2016; 39(4): 589-595
436 Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy
Kobe University Graduate School of Medicine
Cardiovascular Medicine Kuroda M JACC. Cardiovascular Intervention 2015; 8(6): 800-811
437 Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention
Juntendo University School of Medicine
Cardiology Cardiovascular Medicine
Takahashi S Circulation 2015; 132: A18444
438 1,5-anhydro-d-glucitol as a predictor of cerebral infarction in patients with glycated hemoglobin A1c based good diabetes control
Brain Attack Center Ota Memorial Hospital
Siga Y Stroke 2016; 47: ATP208
439 Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes
University Medical Centre Utrecht
Julius Centre for Health Sciences and Primary Care
Ouden Hd Metabolomics 2016; 12:27
440 Glucose peaks and risk of dementia among persons with diabetes: The atherosclerosis risk in communities (ARIC) study
Johns Hopkins University
Rawlings A Circulation 2016; 133(Suppl 1): MP77
441 Association of 1,5-anhydroglucitol with subclinical cardiovascular disease
Johns Hopkins University
Liang M Circulation 2016; 133(Suppl 1): P047
442 The association of serum glycated albumin with the prevalence of diabetic retinopathy in Korean patients with type 2 diabetes mellitus
Kangbuk Samsung Hospital
Endocrinology and Metabolism
Jeon WS Diabetes Res Clin Pract 2016; 116: 46-53
443 Efficacy of metreleptin in patients with type 1 diabetes Vasandani C ADA 2016; 76th 444 Total fat mass and BMI exhibit varying associations with
glycemic markers Carson AP ADA 2016; 76th
32 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 445 Translational genetic approaches for diagnosing
monogenic diabetes in Singapore Gardner D ADA 2016; 76th
446 Comparison of diurnal glycemic variability on day 1 vs. day 7 of treatment with the once-weekly DPP-4 inhibitor trelagliptin
Onishi T ADA 2016; 76th
447 Efficacy and safety of mitiglinide/voglibose fixed-dose combination tablet compared with dipeptidyl peptidase-4 inhibitors: Results of a cross-over study
Keio University Endocrinology, Metabolism and Nephrology
Tanaka M Therapeutic Research 2016; 37(3): 285-291
448 Personalised glycaemic control in critically ill type-2 diabetic patients: An exploratory study
Royal Adelaide Hospital
Intensive Care Unit Kar P Anaesth Intensive Care 2016; 44(2): 307-308
449 Association of CD34/CD133/VEGFR2-positive cell numbers with eicosapentaenoic acid and postprandial hyperglycemia in patients with coronary artery disease
University of Fukui Cardiovascular Medicine Morishita T International Journal of Cardiology 2016; 221: 1039-1042
450 Association of 1,5-anhydroglucitol, a biomarker of glucose peaks, with subclinical cardiovascular disease
Johns Hopkins University
Epidemiology and the Welch Center for Prevention
Liang M Diabetes Care 2016; 39(10): 1752-1759
451 Impact of serum 1,5-anhydro-d-glucitol value on prediction of major adverse cardiac and cerebrovascular events in non-diabetic patients without coronary artery disease
National Center for Global Health and Medicine
Cardiovascular Medicine Ikeda N Atherosclerosis 2016; 253: 1-6
452 Do glycemic marker levels vary by race? Differiing results from a cross-sectional analysis of individuals with and without diagnosed diabetes
University of Alabama
Epideomiology Carson AP BMJ Open Diabetes Research and Care 2016; 4: 1-8
453 Impact of diet on efficacy of insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in East Asian patients with type 2 diabetes: subgroup analysis of the CLASSIFY randomized trial
Peking Union Medical College Hospital
Parenteral and Enteral Nutrition
Chen W J Diabetes Investig 2016 June 11 [Epub ahead of print]
454 1,5-anhydro-D-glucitol could reflect hyperglycemia risk in patients with type 2 diabetes receiving insulin therapy
Seoul National University College of Medicine
Internal Medicine Kim MK Endocrinol Metab 2016; 31: 284-291
455 Serum bilirubin levels are positively associated with glycemic variability in women with type 2 diabetes
Seoul National University College of Medicine
Internal Medicine Kim LK J Diabetes Investig 2016; 7(6): 874-880
456 Factors influencing inter-day glycemic variability in diabetic outpatients on insulin therapy
University of Occupational and Environmental Health
Internal Medicine Mori H J Diabetes Investig 2016 July [Epub ahead of print]
457 Clincial effect of real time pulse rate monitoring with a portable pulsimeter on physical exercise therapy for male patients with type 2 diabetes
Kyorin University School of Medicine
Diabetes, Endocrinology and Metabolism
Sumitani Y Diabetol Int 2016; 7: 228-234
33 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 458 Liberal glycemic control in critically ill patients with type 2
diabetes: An exploratory study University of Adelaide Acute Care Medicine Kar P Critical Care Medicine 2016;
44(9): 1695-1703 459 Achievement rate of glycemic control for therapy with
sitagliptin in type 2 diabetes* Jikei University School of Medicine
Diabetes, Metabolism and Endocrinology
Utsunomiya K Prog. Med. 2015; 35(3): 563-569
460 Effects of switching from dipeptidyl peptidase-4 inhibitors taken once daily to vildagliptin taken twice daily on glycemic control in Japanese patients with type 2 diabetes
Komatsu Clinic Nishiyama K Prog. Med. 2015; 35(9): 1507-1513
461 Usefulness of long-acting exenatide for older diabetic patients with mild cognitive impairment
Kakeyu-Misayama rehabilitation center
Tohyoh S Therapeutic Research 2015; 36(5): 497-502
462 Efficacy and safety of anagliptin add to insulin therapy in Japanese patients with type 2 diabetes
Kawasaki Medical School
Internal Medicine I Kaku K Jpn Pharmacol Ther 2015; 43(12): 1663-1686
463 Efficacy of vildagliptin in patients with type 2 diabetes treated with insulin on glycemic control: Investigation involving switching from another oral hypoglycemic agent
Keio University Endocrinology, Metabolism and Nephrology
Tanaka M Prog. Med. 2016; 36(2): 277-282
464 The pattern of glycemic variability in patients treated with faster-acting insulin*
JCHO Kanazawa Hospital
Internal Medicine Furukawa K Medical Consultation & New Remedies 2016; 53(2): 98-99
465 Efficacy and safety of anagliptin as an add-on to glinides in Japanese patients with type 2 diabetes
Kawasaki Medical School
Internal Medicine I Kaku K Jpn Pharmacol Ther 2016; 44(3): 381-390
466 Relationship of glycemic control markers- 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance
Madras Diabetes Research Foundation and Dr. Mohan's Diabetes Specialities Centre
Aravindakshan T
Indian Journal of Endocrinology and Metabolism 2016; 20(5):690-695
467 Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention
Juntendo University Graduate School of Medicine
Cardiovascular Medicine Takahashi S Cardiovascular Diabetology 2016; 15: 145
468 Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study
Tokyo Medical University
Cardiology Tomiyama H Cardiovascular Diabetology 2016; 15: 150
469 Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial
Saiseikai Kumamoto Hospital
Cardiology Kajiwara M Journal of Cardiology 2017; 69(3): 511-517
470 Repeated 3-minute stair climbing-descending exercise after a meal over 2 weeks increases serum 1,5-anhydroglucitol levels in people with type 2 diabetes
Toyooka Hospital Hidaka Medical Center
Honda H J Phys. Ther. Sci. 2017; 29: 75-78
471 Efficacy and safety of vildagliptin as an add-on therapy in inadequately controlled type 2 diabetes patients treated with basal insulin
Juntendo University Graduate School of Medicine
Metabolism and Endocrinology
Saito D J Clin Med Res. 2017; 9(3): 193-199
34 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 472 Cross-over study comparing postprandial glycemic
increase after addition of a fixed-dose mitiglinide/voglibose combination or a dipeptidyl peptidase-4 inhibitor to basal insulin therapy in patients with type 2 diabetes mellitus
National Center for Global Health and Medicine Center Hospital
Endocrinology and Metabolism
Sugiyama N Med Sci Monit Basic Res 2017; 23: 36-44
473 Excretion rates of 1,5-anhydro-D-glucitol, uric acid and microalbuminuria as glycemic control indexes in patients with type 2 diabetes
Xuhui District Central Hospital
Endocrinology Ma C Scientific Reports 2017 [Epub ahead of print]
474 Serum 1,5-anhydroglucitol levels slightly increase rather than decrease after a glucose load in subjects with different glucose tolerance status
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Endocrinology and Metabolism
Su H Acta Diabetol 2017; 54(5): 463-470
475 Effects of 50mg vildagliptin twice daily vs. 50mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose
Hokkaido University Graduate School of Medicine
Rheumatology, Endocrinology and Nephrology
Nomoto H Endocr J. 2017; 64(4): 417-424
476 Serum 1,5-anhydroglucitol levels slightly increase rather than decrease after a glucose load in subjects with different glucose tolerance status
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Endocrinology and Metabolism
Su H J Diabetes Investig 2017; 8(51): 40
477 Glucose peaks and the risk of demantia and 20-year cognitive decline
Johns Hopkins Blooming School of Public Health
Epidemiology Rawlings A Diabetes Care 2017 May [Epub ahead of print]
478 The glucose-lowering efficacy of sitagliptin in obese Japanese patients with type 2 diabetes
Okayama University Hospital
Center for Innovative Clinical Medicine
Kodera R Internal Medicine 2017; 56: 605-613
479 Comprehensive metabolomic analysis in blood, urine, fat and muscle in men with metabolic syndrome: A randomized, placebo-controlled clinical trial on the effects of resveratrol after four months' treatment
Aarhus University Endocrinology and Internal Medicine
Korsholm AS Int. J. Mol. Sci. 2017; 18: 554
480 1,5-Anhydroglucitol correlates with postprandial glucose in subjects with type 1 diabetes irrespective of HbA1c responder status
University of Sheffield
Heller SR Diabetes 2017; 66(Supplement 1): A260-A261
481 Effect of therapy of weekly GLP-1 analog given monthly for elderly type 2 diabetes patients in Japan
Chubu Rosai Hospital Diabetes and Endocrinology
Imamine R Diabetes 2017; 66(Supplement 1): A285-A286
482 Decreased visceral fat and improved insulin resistance together with enhanced urinary glucose excretion may be involved in the serum uric acid-lowering effect of dapagliflozin
Takeda General Hospital
Diabetes Center Hige H Diabetes 2017; 66(Supplement 1): A334-A335
483 HOMA-IR/1,5-AG ratio is a novel parameter for predicting the incidence of type 2 diabetes: The AYABE study
Ayabe City Hospital Endocrinology and Internal Medicine
Senmaru T Diabetes 2017; 66(Supplement 1): A415
35 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 484 A single dose of dapagliflozin, an SGLT-2 inhibitor,
induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus
Jagiellonian University Medical College
Metabolic Diseases Hohendorff J Endocrine 2017; [Published online June]
485 Plasma mannose levels are associated with incident type 2 diabetes and cardiovascular disease
KTH-Royal Institute of Technology
Science for Life Laboratory
Mardinoglu A Cell Metabolism 2017; 26(2): 281-283
486 Information content of paired measurement of A1C and 1,5-anhydroglucitol relative to post-prandial glucose excursions: a model simulation study
Jefferson University Hospitals
Molligan JD Clinical Chemistry 2016; 62(10, Supplement): S44-S45
487 A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus
Jagiellonian University Medical College
Hohendorff J Diabetologia 2017; 60(Suppl 1): S132
488 1,5-Anhydroglucitol correlates with postprandial glucose in subjects with type 1 diabetes irrespective of HbA1c responder status
University of Sheffield
Heller S Diabetologia 2017; 60(Suppl 1): S312-S313
489 Efficacy and safety of fast-acting insulin aspart are maintained over 52 weeks: comparison with insulin aspart in onset 1
UZ Leuven Mathieu C Diabetologia 2017; 60(Suppl 1): S314
490 Risk factors for severe hypoglycemia in black and white adults with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
Johns Hopkins Bloomberg School of Public Health
Epidemiology and the Welch Center for Prevention
Lee AK Diabetes Care 2017; September [Epub ahead on line]
36 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
Screening
No. Title Institute Department First Author Citation
1 Diabetes mellitus and 1,5-anhydro-D-glucitol JR Tokyo General Hospital
Internal Medicine Ishii S The Journal of Japan Physicians Association 1990; 4(3): 329-330
2 Comparison of 1,5-anhydroglucitol, HbA1c, fructosamine for detection of diabetes mellitus
University of Teikyo Internal Medicine Yamanouchi T Diabetes 1991; 40(1): 52-57
3 Combination assay of 1,5-anhydro-D-glucitol with fasting blood glucose, HbA1c and fructosamine as a screening for diabetes mellitus
JR Tokyo General Hospital
Internal Medicine Ishi S J. of Transportation Med. 1991; 45(3): 99-104
4 Assay of 1,5-Anhydroglucitol for screening for diabetes* Tohoku Kouseinenkin Hospital
Internal Medicine Goto Y Diabetes Frontier 1992; 3(4): 403-406
5 Efficacy of hemoglobin A1c, fructosamine and 1,5-anhydroglucitol as screening tests for diabetes in local communities*
Jichi Medical University Public Health Nagai M Japanese Journal of Public Health 1993; 40(3): 205-212
6 Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening?
Human Diabetes and Metabolism Research Centre
Robertson DA Diabetes Medicine 1993; 10(1): 56-60
7 Relationship between multiple diagnosis of diabetes and physical risk in island population*
Nagasaki University Public Health Sueda H Nagasaki Medical Journal 1993; 68(2): 231-242
8 preliminary of screening for diabetes using 1,5-anhydroglucitol*
Fukuoka Kuroki Health Center
Tomooka Y The Journal of Public Health Practice 1993; 57(12): 890-892
9 A study of 1,5-anhydroglucitol as a marker in screening diabetes mellitus
Kameda General Hospital
Clinical Laboratory Noto K Official Journal of the Japanese Society of Human Dry Dock 1993; 8(2): 31-34
10 Improvement of the sensitivity of glucose intolerance screening by combining 1,5-AG, hemoglobin A1c and fasting blood glucose
Mitsui Memorial Hospital
Central Clinical Laboratory
Yano M J. Japan Diab. Soc. 1995; 38(4): 255-260
11 Significance of 1,5-Anhydroglucitol in total health check - Usefulness in the screening of diabetes mellitus and effect of renal dysfunction on it -
Aichi Health Center Tsushita K Japanese Journal of Multiphasic Health Testing and Service 1994; 21(2): 118-122
12 Significance of serum 1,5-anhydroglucitol measurements for screening of diabetes mellitus in human dry dock
Kyoto Second Red Cross Hospital
Internal Medicine Okajima Y Official Journal of the Japanese Society of Human Dry Dock 1993; 8(1): 63-66
13 Diagnostic significance of plasma 1,5-anhydroglucitol measurement in screening for diabetes mellitus
Fukushima Medical College
Internal Medicine Nemoto T J. Japan Diab. Soc. 1995; 38(12): 921-929
14 Comparison of 1,5-anhydroglucitol, HbA1c, fructosamine for screening of diabetes mellitus
Keio University Preventive Medicine and Public Health
Miyakawa M Health Science 1996; 12(1): 44-53
15 Efficacy of hemoglobin-A1c, fructosamine and 1,5-anhydroglucitol in screening for diabetes mellitus
Tochigi Public Health Service Association
Nagashima Y Journal of Preventive Medicine 1994; 294: 42-46
37 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
16 Effect of age and obesity on glycated haemoglobin and 1,5-anhydroglucitol in screening for type 2 diabetes mellitus
Gunma University School of Medicine
Laboratory Medicine
Tsukui S Diabetes Medicine 1995; 12: 899-903
17 Improvement the accuracy of screening tests for diabetes mellitus with a logistic regression model
Gunma University School of Medicine
Laboratory Medicine
Tsukui S J. Japan Diab. Soc. 1996; 39(4): 241-246
18 Screening of glucose intolerance with fasting blood samples Mitsui Memorial Hospital
Internal Medicine Siba T Japanese Journal of Clinical Medicine 1996; 54(10): 2800-2806
19 Decreased serum 1,5-anhydroglucitol in nondiabetic subjects with a family history of NIDDM
Gunma University School of Medicine
Laboratory Medicine
Tsukui S Diabetes Care 1996; 19(9): 940-944
20 Efficacy of 1,5-anhydroglucitol in screening for impaired glucose tolerance*
Saiseikai Matsuyama Hospital
Clinical Laboratory Yamauchi M The Ehime Journal of Medical Technology 1997; 16: 47-49
21 Screening of glucose intolerance with fasting blood samples Mitsui Memorial Hospital
Internal Medicine Siba T Japanese Journal of Clinical Medicine 1997; 55(Special Edition 1997): 904-909
22 Economic evaluation of alternative indicator for screening for diabetes mellitus
Keio University Preventive Medicine and Public Health
Sirasaya K Preventive Medicine 1999; 29: 79-86
23 Study on cut-off point of 1,5-anhydroglucitol Aichi Health Center Yamamoto K Japanese Journal of Multiphasic Health Testing and Service 1999; 26(3): 241-245
24 Diagnosis and tests for impaired glucose tolerance and borderline type
Hiroshima Atomic Bomb Casualty Council
Health Management & Promotion Center
Ito C Japanese Journal of Clinical Medicine 2005; 63(Special Edition 2): 355-360
25 Plasma anhydro-D-glucitol Hiroshima Medical Association Clinical Laboratory Center
Maeda R Japanese Journal of Clinical Medicine 2005; 63(Special Edition 2): 386-389
26 Diagnosis and tests for diabetes mellitus Hokkaido University School of Medicine
Internal Medicine Niwa H KLINIKA 2004; 31(6): 384-389
27 Screening method for postprandial hyperglycemia using 1,5-anhydroglucitol combined with fasting plasma glucose
Foundation of Kinki Health Administration Center
Shiga Department Clinic
Kanazawa Y J. Japan Diab. Soc. 2006; 49(5): 319-323
28 Effective screening method and follow-up for diabetes mellitus*
Hiroshima Atomic Bomb Casualty Council
Health Management & Promotion Center
Ito C Diabetes Up date 2006; 22: 20-29
29 6. Health checkup・Screening for glucose intolerance in ningen dock checkup*
Jikei University School of Medicine
Wada T Prog. Med. 2006; 26(9): 2097-2100
30 Study using random allocation on the long-term effectiveness of short-term health education programs for prevention of diabetes in middle-aged and elderly subjects
Iwate Medical University
Hygiene and Preventive Medicine
Itai K Health management association research grant bulletin 2007; 23: 9-14
38 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
31 Screening method for postprandial hyperglycemia using 1,5-anhydroglucitol in order to discover subjects with postprandial hyperglycemia in Ningen Dock
Foundation of Kinki Health Administration Center
Shiga Department Clinic
Kanazawa Y Official Journal of Japan Society of Ningen Dock 2008; 23(3): 570-574
32 Screening for type 2 diabetes in obese youth Univ. Texas Southwestern Medical Center
Pediatrics Shah S Pediatrics 2009; 124: 573-579
33 Efficacy of 1,5-anhydroglucitol in screening for diabetes mellitus*
Asahi General Hospital Central Clinical Laboratory
Hiiro J The Medical Journal of Asahi General Hospital 2009; 31: 10-13
34 Question: Efficacy of markers for screening for prediabetes* Yokkaichi Social Insurance Hospital
Clinical Laboratory Kato M Obesity & diabetes 2011; 10(4): 541-544
35 Are current diagnostic guidelines delaying early detection of dysglycemic states? Time for new approaches
NYU School of Medicine
Bergman M Endocrine 2013; 44(1): 66-69
36 Relationship between serum 1,5-AG levels and macrovascular disease (coronary heart diseases, strokes) in Suita study*
Keio University Preventive Medicine and Public Health
Okamura T Study Report 2013: 53-60
37 Usefulness of postmortem 1,5-anhydroglucitol analysis in forensic diagnosis
Ehime Prefectural University of Health Sciences
Medical Technology
Takaya T Japanese Journal of Medical Technology 2014; 63(6): 680-686
38 Diabetes screening in the workplace by a single casual blood sampling using HbA1c, fructosamine and 1,5-AG: An application of stepwise regression analysis
Hokkaido Chuo Rosai Hospital
Kaji H J. Nor. Occ. Health 2013; 49: 23-28
39 Measurement of postmortem 1,5-anhydroglucitol in vitreous humor for forensic diagnosis
Ehime Prefectural University of Health Sciences
Medical Technology
Takata T J Forensic Sci. 2016; 61(Suppl 1): S150-S153
40 Rational diagnosis of diabetes: the comparison 1,5-anhydroglucitol with other glycemic markers
Ufuk University Internal Medicine Malkan UY SpringerPlus 2015; 4: 587
41 Obesity-related metabolite profiles of black women spanning the epidemiologic transition
Loyola University Chicago
Public Health Sciences
Dugas LR Metabolomics 2016; 12: 45
42 Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes
Zhongda Hospital Southeast University
Endocrinology Wang Y Acta Diabetol 2016 November [E-pub ahead of print]
43 The establishment of biological reference intervals of nontraditional glycemic markers in a Chinese population
The Second Affiliated Hospital of Anhui Medial University
Clinical Laboratory Zhou Q J Clin Lab Anal 2016; 1-7
44 Serum 1,5-anhydroglucitol when used with fasting plasma glucose improves the efficiency of diabetes screening in a Chinese population
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Endocrinology and Metabolism
Ying L Sci Rep. 2017 ; 7(1): 11968
39 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
Pediatrics
No. Title Institute Department First Author Citation
1 1-Deoxyglucose (1,5-Anhydroglucitol); A novel metabolic parameter of diabetes*
National Defense Medical College
Pediatrics Yoshioka S Pediatrics of Japan 1983; 24(4): 405-410
2 1-Deoxyglucose (1,5-Anhydroglucitol), Sorbitol (Glucitol) National Defense Medical College
Pediatrics Fujitsuka S Japanese Journal of Pediatric Medicine 1990; 22(2): 211-216
3 Usefulness of determination of serum 1,5-anhydroglucitol in screening for diabetes mellitus in children
Niigata University Pediatrics Asami T The Journal of Child Health 1991; 50(3): 389-391
4 Clinical significance of 1,5-anhydroglucitol in children with diabetes mellitus*
Nihon University Hospital
Pediatrics Urakami T The Journal of Pediatric Practice 1992; 55(3): 448-451
5 Clinical significance of SMBG and 1,5-anhydroglucitol for glycemic control in children with insulin-dependent diabetes mellitus*
Nihon University Hospital
Pediatrics Urakami T Self measurement of blood glucose and management of diabetes 1992; 10th Symposium: 59-63
6 Screening and diagnosis for diabetes mellitus in children* Osaka Rosai Hospital Pediatrics Konishi K The Journal of Pediatric Practice 1993; 56(8): 1522-1527
7 Education of glycemic control* Nihon Medical University
Pediatrics Ooki Y The Journal of Pediatric Practice 1993; 8(77): 1551-1557
8 Study on serum concentration and urinary excretion of 1,5-anhydro-D-glucitol in children with insulin-dependent diabetes mellitus
National Defense Medical College
Pediatrics Fujitsuka S J Jpn Pediatr Soc 1993; 97(6): 1360-1372
9 Evaluation of serum 1,5-Anhydro-D-glucitol in children with diabetes mellitus
Osaka Medical College Pediatrics Tokuda M Clinical Endocrinology 1992; 40(9): 869-873
10 Reliability of 1,5-Anhydro-D-glucitol as a Marker for Detection of Diabetes and an Indicator of Glycemic Control in Insulin-dependent Diabetes Mellitus Children
Nihon University Pediatrics Urakami T Clin Pediatr Endocrinol 1995; 4(1): 25-31
11 Study on polyol metabolism in children with insulin dependent diabetes mellitus*
Hiroshima University School of Medicine
Pediatrics Jinno K Hiroshima M.J. 1998; 46(3,4): 99-106
12 Urinary glucose screening for diabetes mellitus in Kumamoto city - Results and problems over the past 24 years -
Kumamoto University School of Medicine
Pediatrics Kiwaki K J Jpn Pediatr Soc 2001; 105(2): 94-99
13 The associaiton between Juvenile obesity and 1,5-Anhydroglucitol(1,5AG)
Jikei University School of Medicine
Diabetes, Metabolism and Endocrinology
Miyashita Y Diabetes 2007; 50(supple1): S237
14 Serum 1,5-anhydroglucitol (Glycomark TM) levels in children with and without type1 diabetes mellitus
Clinical Care Center Pediatric Nguyen TM Pediatr. Diabetes 2007; 8(4): 214-219
15 Education of diabetes for 7 years-old-girl with type 1 diabetes* National Center for Global Health and Medicine
pharmacology Kanazawa N The Pharmaceuticals 2011; 53(6): 869
40 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
16 Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls
Joslin Diabetes Center Pediatric Mehta SN Pediatric Diabetes 2011; 13: 278-284
17 Metabolomic profiles predicting type 1 diabetes Wittmann B Diabetes 2012; 61(SUPPL1): A367
18 The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitol, and continuous glucose monitoring
Jaeb center for health research
Laboratory Medicine
Beck R Pediatric Diabetes 2011; 12: 690-695
19 Glycemic control indicators in patients with neonatal diabetes mellitus
Asahikawa Medical University
Pediatrics Suzuki S World J Diabetes 2014; 5(2): 198-208
20 Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia - 1,5-anhydroglucitol, fructosamine, and glycated albumin
Children's Hospital Colorado
Pediatrics Chan CL Pediatric Diabetes 2016; 17: 206-211
21 Body mass index and indicators of adiposity are adversely associated with cardiovascular biomarkers in youth with type 1 diabetes over 18 months
NICHD Lipsky LM Circulation 2015; 131: AP135
22 1,5-anhydroglucitol, a discriminatory gas chromatography-mass spectrometry(GC-MS) metabolomic marker in adolescents with type 1 diabetes- quantified using the plasma Glycomark assay
Lady Cilento Children's Hospital
Endocrinology Conwell LS Pediatric Diabetes 2015; 16(Suppl. 21): 41-42
23 Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes
Konkuk University Medical Center
Pediatrics Yoo HY Ann Pediatr Endocrinol Metab 2015; 20: 192-197
24 Greater diet quality is associated with more optimal glycemic control in a longitudinal study of youth with type 1 diabetes
Ennice Kennedy Shriver national Institute of Child Health and Human Development
Health Behavior Branch
Nansel TR Am J Clin Nutr 2016; 104(1): 81-87
25 Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes
Children's Hospital Colorado and University of Colorado Anschutz Medical Campus
Pediatric Endocrinology
Chan CL Pediatr Diabetes 2016; : 1-8
26 Physical activity (PA) in youth with type 1 diabetes (T1D): variable impact on metabolic outcomes
Joslin Diabetes Center Pediatric, Adolescent and Young adult section
Giani E Pediatric Diabetes 2016; 17(Suppl. 24): 148
27 Glycemic control and variability in association with body mass index and body composition over 18 months in youth with type 1 diabetes
Eunice Kennedy Shriver national Institute of Child Health and Human Development
Health Behavior Branch
Lipsky LM Diabetes Res Clin Pract 2016; 120: 97-103
41 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
Pregnancy
No. Title Institute Department First Author Citation
1 1-Deoxyglucose (1,5-anhydro-D-glucitol) concentration during pregnancy and puerperium
Kurume University School of Medicine
Obstetrics Gynecology
Nakayama Y ACTA OBST GYNAEC JPN 1987; 39(9): 1657-1658
2 Serum levels of 1,5-anhydro-D-glucitol during the normal and diabetic pregnancy and puerperium
Kurume University School of Medicine
Obstetrics Gynecology
Tetsuo M Acta Obset Gynecol Scand 1990; 69: 479-485
3 Efficacy of 1,5-Anhydro-D-glucitol in screening for gestational diabetes mellitus*
Kurume University School of Medicine
Obstetrics Gynecology
Yoshimatsu K Practice 1991: 18-26
4 Clinical significance of 1,5-anhydroglucitol in pregnant women with normal and abnormal glucose tolerance*
Asahikawa Medical University
Obstetrics Gynecology
Sasaki K The World of Obstetrics and Gynecology 1992; 44(2): 17-22
5 Serum 1,5-anhydroglucitol (1,5-AG) in pregnant diabetic Tokyo Women's Medical College
Diabetes Center Sanaka M J. Japan Diab. Soc. 1993; 36(2): 93-100
6 Fetal and maternal 1,5-anhydroglucitol (1,5-AG) in pregnant rats Part II: Distribution of 1,5-AG in normal pregnant rats
Tokyo Women's Medical College
Internal Medicine Morita Y J Tokyo Wom Med Univ 1993; 63(2): 64-69
7 Serum 1,5-anhydroglucitol (1,5-AG) in pregnant diabetics at delivery and in cord serum
Tokyo Women's Medical College
Diabetes Center Sanaka M J. Japan Diab. Soc. 1993; 36(2): 93-100
8 Fetal and maternal 1,5-anhydroglucitol (1,5-AG) in pregnant rats Part I: Alteration of serum 1,5-AG in normal pregnant rats
Tokyo Women's Medical College
Internal Medicine Morita Y J Tokyo Wom Med Univ 1993; 63(2): 191-195
9 Efficacy of 1,5-anhydroglucitol (AG) in management for gestational diabetes mellitus*
Hirosaki University School of Medicine
Obstetrics Gynecology
Tanaka M Practice 1991: 41-47
10 Disorders of carbohydrate metabolism Mie University School of Medicine
Obstetrics Gynecology
Toyoda N Journal of Clinical Laboratory Medicine 1997; 41(7): 783-787
11 Application of GC/MS analysis of urinary sugar and sugar-alcohols to the clinical management of pregnant woman with abnormal carbohydrate metabolism
Tetsuo Hospital Tetsuo M Proceedings of the Japanese Society for Biomedical Mass Spectrometry 1998; 23: 89-93
12 The predictive value of serum 1,5-anhydro-D-glucitol in pregnancies at increased risk of gestational diabetes mellitus and gestational impaired glucose tolerance
The Chinese Univ of HongKong
Obstetrics and Gynaecology
Wing-Hung Tam
Br J Obstet Gynaecol 2001; 108: 754-756
13 Plasma anhydro-D-glucitol(1,5-AG) as an indicator of hyperglycaemic excursions in pregnant women with diabetes
Poznan University of medical
Pharmacology M. Dworacka Diabetic Medicine 2005; 23: 171-175
14 Evaluation of 1,5-anhydroglucitol as marker of glycemic control and birth weight in pregnancy complicated by type 1 diabetes mellitus
Nowak N Diabetes 2012; 61(SUPPL1): A51
15 Metabolomics reveals broad-scale metabolic perturbations in hyperglycemia mothers during pregnancy
Scholtens DM Diabetes 2012; 61(SUPPL1): A340
42 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
16 1,5-anhydroglucitol (1,5-AG) is strongly associated with neonatal birth weight across all trimesters in pregnancy complicated by diabetes
University of Washington
Medicine/Metabolism Wright L A-C Endocr Rev 2012; 33(03_MeetingAbstract)
17 Interpretation of plasma 1,5-anhydroglucitol in pregnancy using a novel approach to establishing reference change values
Diagnostic Service of Manitoba
Burton TR Clinical Biochemistry 2012; 45(Issues13-14): 1103
18 Evaluation of 1,5-anhydroglucitol as marker of glycaemic control and birth weight in pregnancy complicated by type 1 diabetes mellitus
Jagiellonian University
Metabolic Diseases Nowak N Diabetologia 2012; 55(Suppl1): S437
19 1,5-anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus
Jagiellonian University
Metabolic Diseases Nowak N Diabetologia 2013; 56: 709-713
20 1,5-anhydroglucitol(1,5AG) and neonatal complications in pregnancy complicated by diabetes
Univ. of Washington Endocrinology Wright LA 49th EASD 2013; No.1293
21 Metabolomics reveals broad-scale metabolic perturbations in hyperglycemic mothers during pregnancy
Northwestern University
Feinberg school of Medicine
Scholtens DM Diabetes Care 2014; 37(1): 158-166
22 1,5 Anhydroglucitol serum concentration as a biomarker for screening gestational diabetes in early pregnancy
Federal University of Parana
Clinical Analysis Boritza KC Clin Chem Lab Med 2014; 52(8): e179-e181
23 1,5-anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus
Jagiellonian University
Metabolic Diseases Nowak N Diabetes Technology & Therapeutics 2014; 16(SUPPL.1): S72
24 1,5 Anhydroglucitol and neonatal complications in pregnancy complicated by diabetes
University of Washington Medical Center
Wright LA Endocr Pract. 2015; 21(7): 725-733
25 1,5-Anhydroglucitol: a new predictor of neonatal birth weight in diabetic pregnancies
University of Washington
Obstetrics & Genecology
Delaney SS Eur J Obstet Gynecol Reprod Biol. 2015; 189: 55-58
26 The early bird catches the worm - predicting the onset of gestational diabetes in the first trimester
Rotunda Hospital Obstetrics & Genecology
Corcoran S J Matern Fetal Neonatal Med 2015; 28(7): 823-824
27 Epidemiology of dysglycemia in pregnant Oklahoma American Indian women
University of Oklahoma Health Sciences Center
Endocrinology Azar M J Clin Endocrinol Metab 2015; 100(8): 2996-3003
28 Indicators of glycemic control in patients with gestational diabetes mellitus and pregnant women with diabetes mellitus
NTT West Osaka Hospital
Internal Medicine Hashimoto K World J Diabetes 2015; 6(8): 1045-1056
29 Correlation between GlycoMark values as an index of glucose levels in pregnant diabetic women and the rate of clinical diabetic complications in infants
Emek Medical Center Ob & Gyn Nachum Z Am J Obstet Gynecol 2016; 214(Suppl 1): S353-S354
43 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
30 Low levels of serum 1,5-anhydroglucitol during pregnancy compared to blood glucose measured by continuous glucose monitoring
Kitasato University Health Care Center Moriya T Annals of Clinical & laboratory Science 2016; 46(2): 227-228
31 Metabolomic profiling of second trimester amniotic fluid from mothers with diabetes during pregnancy shows evidence of altered fetal metabolism
Alexander J ADA 2016; 76th
32 The association of glycemic markers with plasma adipocytokine levels in women with gestational diabetes
Istanbul University Endocrinology and Metabolism
Oztop N J Diabetes Metab 2016; 7(9)
33 The relationship between proinflammatory cytokines and glycemic markers in gestational diabetes
Istanbul University Dinccag N Diabetes 2017; 66(Supplement 1): A389
34 Maternal and neonatal outcomes and 1,5-anhydroglucitol in pregnancies complicated by diabetes
University of Washington School of Medicine
Walker CL ADA 2017; 77th
35 A computational model of 1,5-AG dynamics during pregnancy
Broad Institute of MIT and Harvard
Zekavat SM Physiological Reports 2017; 5(16): e13375
44 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
Renal Function
No. Title Institute Department First Author Citation 1 The influence of renal failure on diabetic marker, 1,5-anhydro-
D-glucitol, I. - the relation between 1,5-anhydroglucitol and creatinine in serum levels -
Gunma University School of Medicine
Internal Medicine Kohama T Japanese Journal of Medicine and Pharmaceutical Science 1991; 25(3); 697-701
2 The influence of renal failure on diabetic marker, 1,5-anhydro-D-glucitol, II. - the relation between 1,5-anhydroglucitol and urinary albumin -
Gunma University School of Medicine
Internal Medicine Shimizu M Japanese Journal of Medicine and Pharmaceutical Science 1991; 25(3): 703-706
3 Low serum 1,5-anhydroglucitol concentrations in patients with chronic renal failure
Kanto Teishin Hospital Endocrinology and Metabolism
Harada H J. Japan Diab. Soc. 1991; 34(2): 163-166
4 Plasma 1,5-anhydroglucitol concentration in patients with End-stage renal disease with and without Diabetes mellitus
Osaka City University Medical School
Internal Medicine Emoto M Nephron 1992; 61: 181-186
5 Fractional excretion of 1,5-anhydroglucitol Ehime University School of Medicine
Internal Medicine Murakami T J. Japan Diab. Soc. 1993; 31(1): 59-61
6 Effect of enal function on serum 1,5-anhydroglucitol Toranomon Hospital Renal Center Yokoyama K Kidney and Dialysis 1993; 25(3): 415-417
7 Urinary excretion of 1,5-anhydroglucitol (1,5-AG) in patients with diabetic
Juntendo University School of Medicine
Nephrology Takeuchi K Kidney and Dialysis 1993; 35(6): 993-997
8 Quantification of 1,5-anhydroglucitol in uremic serum by LC/MS
Nagoya University Branch Hospital
Clinical Laboratory Niwa T Proceedings of the Japanese Society for Biomedical Mass Spectrometry 1993; 18: 185-188
9 Serum 1,5-anhydroglucitol concentrations in non-diabetic patients with chronic renal failure
Gifu City Hospital Internal Medicine Noguchi T Annual of Gifu City Hospital 1993; 13: 1-6
10 Guanidinoacetic acid in serum, urine and renal cortex from streptozotocin-induced diabetic rats
Juntendo University School of Medicine
Nephrology Kiyatake I Clinical and Experimental Nephrology 1994; 36(6): 709-714
11 1,5-Anhydroglucitol as a Marker for the Differential Diagnosis of Acute and Chronic Renal Failure
Kanbara Municipal Hospital
Internal Medicine Yamada H Nephron 1996; 73: 707-709
12 Plasma 1,5-anhydro-D-glucitol concentration and its relation to other plasma components in renal failure and renal transplant recipients
The Queen Elizabeth Hospital
Endocrine & Diabetes
Phillipov G Clin. Chim. Acta 1996; 247: 51-58
13 Renal Tubular Function Affects Glycosuria-Related Urinary Excretion of 1,5-Anhydroglucitol
Osaka City University Medical School
Geriatric Medicine Fujisawa T Diabetes Care 1999; 22(5): 863-864
14 Serum concentration and renal handling of 1,5-anhydro-D-glucitol in patients with chronic renal failure
Kansai Medical University
Internal Medicine Shimizu H Ann Clin Biochem 1999; 36: 749-754
15 Markers of glucose tolerance - management of diabetes* Tokyo Women's Medical College
Diabetes Center Inoue A The Japanese Journal of Clinical Dialysis 2005; 21(7): 844-851
16 Glycemic control of diabetes patients or dialysis Okayama University Graduate School of Medicine
Medicine and Clinical Science
Fukuoka K Kidney and Dialysis 2007; 63(5): 649-654
45 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 17 Hyperglycemia and diabetic renal change in a model of
polyvinyl alcohol bioartificial pancreas transplantation Kyoto University Organ
Reconstruction and Biomaterials
Sakata N Pancreas 2007; 22(5): 602-603
18 Glucose metabolism in diabetic patients with chronic renal failure
Saitama Medical University
Endocrinology and Diabetes
Yamaguchi M Clinical Endocrinology 2008; 56(4): 411-417
19 Question: Relationship between postprandial hyperglycemia and renal tubular function*
Nippon Medical School Internal Medicine Ouchi M Obesity & diabetes 2008; 7(6): 821-823
20 Close relationship between serum concentrations of 1,5-anhydroglucitol and uric acid in non-diabetic male subjects implies common renal transport system
Kinki General Hospital Internal Medicine Koga M Clin Chim Acta. 2009; 410: 70-73
21 Renal failure* Japanese Red Cross Kumamoto Hospital
Chouno M Clinical nursing practice 2010; 31(1): 90-100
22 Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction
Kangbuk Samsung Hospital
Internal Medicine Kim WJ Diabetes Care 2012; 35: 281-286
23 Use of complementary markers in assessing glycaemic control in patients with diabetes and chronic kidney disease undergoing iron or erythropoiesis stimulating agents
University of Hull Diabetes Konya J Diabetic Medicine 2012; 29(Supp.1): 5-6
24 Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment
University of Hull Diabetes and Endocrinology
Konya J Diabet Med. 2013; 30(10): 1250–1254
25 Serum uric acid in relation to serum 1,5-anhydroglucitol levels in patients with and without type 2 diabetes mellitus
Nippon Medical School Internal Medicine Ouchi M Clinical Biochemistry 2013; 46(15): 1436-1441
26 Change in urinary N-acetyl-β-D-glucosaminidase levels relevant to postprandial glycemic control conditions in subjects without diabetes mellitus
Nippon Medical School Internal Medicine Ouchi M Clin Chim Acta 2014; 433: 88-92
27 Postprandial glycemic control conditions in relation to urinary N-acetyl-β-D-glucosaminidase in patients with type 2 diabetes mellitus without low glomerular filtration rate
Nippon Medical School Internal Medicine Ouchi M Diabetes technology & therapeutics 2014; 16(1): 41-47
28 Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?
Ghent University Hospital
Renal division Speeckaert M Nephrol Dial Transplant 2014; 0: 1-11
29 Relationship between serum 1,5-anhydroglucitol, as an indicator of postprandial glycemic control and serum uric acid, considering the renal threshold for glucosuria in the elderly
Nippon Medical School Internal Medicine Ouchi M J Nippon Med Sch 2014; 81(3): 188-189
30 Serum metabolomic profiling and incident CKD among African Americans
University of Texas Health Science Center at Houston
Epidemiology Yu B Clinical Journal of the American Society of Nephrology 2014; 9(8): 1410-1417
31 Glycemic management in ESRD and earlier stages of CKD Joslin Diabetes Center Renal division Williams ME Am J Kidney Dis. 2014; 63(2): S22-S38
46 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation 32 Association between pulse wave velocity and a marker of renal
tubular damage(N-acetyl-β-D-glucosaminidase) in patients without diabetes
Dokkyo Medical University School of Medicine
Pharmacology and Toxicology
Ouchi M J Clin Hypertens 2015; 17(4): 290-297
33 Metabolite markers of incident CKD risk Massachusetts General Hospital
Nephrology Rhee EP Clin J Am Soc Nephrol 2014; 9(8): 1344-1346
34 Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in CKD stages I-III: a comparative study with HbA1c and glycated albumin
Diabetesinstitut Heidelberg
Clinical Studies Hasslacher C J of Diabetes 2016; 8: 712-719
35 Metabolomics reveals differential changes in the energy generating pathways of the detrusor and urothellium caused by diabetes
Wang Y Journal of Urology 2016; 195(4S supplement): e414
36 Interactions between kidney disease and diabetes: dangerous liaisons
School of Medicine, Pontificia University Católica do Paraná
Pecoits-Fiho R Diabetol Metab Syndr 2016; 8: 50
37 Serum levels of 1,5-anhydroglucitol and risk of incident end-stage renal disease
Johns Hopkins Bloomberg School of Public Health
Epidemiology Rebholz CM Am J Epidemiol. 2017; 186(8): 952-960
47 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
Other Diseases
No. Title Institute Department First Author Citation
1 Clinical significance of serum 1,5-Anhydroglucitol (AG) concentration in patients with liver cirrhosis
Osaka Prefectural Hospital
Gastroenterology and Metabolism
Kanda T Medical Journal of Osaka Prefectural General Hospital 1990; 13(1):15-18
2 A clinical study of 1,5-anhydro-D-glucitol in sera of malignant tumor patients
Saitama Cancer Center
Clinical Laboratories Ishii M Japanese Journal of Medicine and Pharmaceutical Science 1991; 25(3): 691-696
3 Serum 1,5-Anhydroglucitol concentrations in patients with liver cirrhosis
Kanazawa University First Department of Internal Medicine
Yamagishi S J. Japan Diab. Soc. 1992; 35(5): 381-384
4 Clinical significance of serum 1,5-Anhydroglucitol level in liver cirrhosis
Osaka Prefectural Hospital
Gastroenterology and Metabolism
Kanda T J. Japan Diab. Soc. 1992; 35(11): 899-907
5 Clinical significance of HbA1c serum fructosamine and 1,5-AG in diabetic patients complicated with liver cirrhosis
Osaka Prefectural Hospital
Gastroenterology and Metabolism
Kanda T J. Japan Diab. Soc. 1993; 36(11): 847-854
6 Clinical studies of long-term glycemic control markers in patients with chronic liver disease
Fukui-ken Saiseikai Hospital
Internal Medicine Bando Y J. Japan Diab. Soc. 1997; 40(1): 17-24
7 Clinical evaluation of serum 1,5AG levels in patients with liver cirrhosis
Kanazawa University Hospital
Clinical Laboratories Shibayama M Rinsho Byori 1997; 45(12): 1187-1190
8 Treatment of diabetes mellitus complicated with liver cirrhosis Osaka Prefectural Hospital
Gastroenterology and Metabolism
Kanda T Clinic All-Round 1998; 47(6): 1910-1917
9 Polyol Profiles in Down Syndrome National Institute on Aging
Laboratory of Neurosciences
Shetty HU J Clin Invest 1995; 95(2): 542-546
10 Serum 1,5-anhydro-D-glucitol levels in liver cirrhosis Kanazawa University School of Medicine
Biochemistry Yamagishi S Acta Diabetol 1998; 35: 65-66
11 Treatment of diabetes mellitus complicated with liver cirrhosis* Osaka Prefectural Hospital
Gastroenterology and Metabolism
Kanda T medicina 2000; 37(13): 2002-2004
12 Glycemic control marker in diabetes with liver cirrhosis Kawasaki Medical School
Internal Medicine Oomoto K Medical Practice 2000; 17(10): 1755
13 1,5-anhydroglucitol assay does not correlate with oral glucose tolerance test in cystic fibrosis patients
Walter Reed Army Medical Center
Endocrinology Kinnaird KEH Endocr Pract. 2009 Oct 15, 1-10[Epub ahead of print]
14 Effects of thyroid hormone on A1C and glycated albumin levels in nondiabetic subjects with overt hypothyroidism
The Catholic University of Korea
Internal Medicine Kim MK Diabetes Care 2010; 33(12): 2546-2548
15 1,5-Anhydroglucitol levels are low irrespective of plasma glucose levels in patients with chronic liver disease
Kinki Central Hospital Internal Medicine Koga M Annals of Clinical Biochemistry 2011; 48: 121-125
16 Lack of correlation between 1,5-anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis
Walter Reed Army Medical Center
Endocrinology Kinnaird KEH Endocrine practice 2010; 16(2): 167-170
17 Method-dependent HbA1c values in a family with hemoglobin Himeji
Kuma Hospital Nishihara E Clinica Chimica Acta 2011; 412: 1689-1692
48 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
18 Glycemic variability is an independent prognostic factor for development of hepatic fibrosis in nonalcoholic fatty liver disease
Kochi Medical School Gastroenterology and Hepatology
Ono M Journal of Hepatology 58 (suppl.1), S545, 2013
19 Metabolomics profile of response to supplementation with β-carotene in the alpha-tocopherol, beta-carotene cancer prevention study
National Cancer Institute
Nutritional Epidemiology Branch
Mondul AM Am J Clin Nutr 2013; 98: 488-493
20 Metabolomics in epidemiology: Sources of variability in metabolite measurements and implications
National Cancer Institute
Cancer Epidemiology and Genetics
Sampson JN Cancer Epidemiol Biomarkers Prev. 2013; 22(4): 631-640
21 Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease
Kochi Medical School Hospital
Gastroenterology and Hepatology
Ochi T Hepatology 2013; 58(4) suppl: 505A
22 Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease
Kochi Medical School Gastroenterology and Hepatology
Hashiba M PLOS ONE 2013; 8(11): 1-9
23 Metabolome analysis for diagnostic approach to gastroenterological cancer
Kobe University Graduate School of Medicine
Gastroenterology Suzuki M The Cell 2014; 46(3): 107-110
24 Metabolome alteration in critical illness according to vitamin D status: A prospective cohort study
Brigham and Woman's Hospital
Renal Division Christopher K Crit Care Med 2014; 42(12 Suppl.): A1443
25 Biomarker discovery for the pancreatic cancer by the serum metabolomics based on gas chromatography mass spectrometry
Kobe University Gastroenterology Kobayashi T SHIMAZU Review 2014; 70(3,4): 117-121
26 Hyperglycemia in patients with hematologic malignancies The Ohio State University Wexner Medical Center
Endocrinology Healy SJ Curr Diab Rep 2015; 15: 8
27 Searching biomarkers by metabolome analysis* Kobe University Graduate School of Medicine
Metabolomics Research
Yoshida M Sysmex Scientific Seminar 2014; 37th: 39-45
28 Gastroenterological cancer diagnosis by metabolomics-discovery of pancreatic cancer biomarker
Kobe University Graduate School of Medicine
Metabolomics Research
Yoshida M Rinsyo Byori 2015; 63(4): 450-456
29 Plasma metabolite biomarkers for the detection of pancreatic cancer
Shanghai Key Laboratory of Diabetes Mellitus
Translational Medicine
Xie G Journal of Proteome Research 2015; 14(2): 1195-1202
30 Dose-finding quantitative 18F-FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecologic malignancies
Imperial College London
Ovarian Cancer Action Research Centre
Gungor H J Nucl Med 2015; 56(12): 1828-1835
31 Urine metabolite profiles predictive of human kidney allograft status
Weill Cornell Medical College in Qatar
Physiology and Biophysics
Suhre K J Am Soc Nephrol 2016; 27(2): 626-636
49 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
32 Pancreatic cancer screening using a multiplatform human serum metabolomics system
Kobe University Graduate School of Medicine
Gastroenterology Sakai A Biomark. Med. 2016; 10(6): 577-586
33 Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer
National Cancer Center Research institute
Chemotherapy & Clinical Research
Honda K Biomark. Med. 2016; 10(11): 1197-1207
34 Metabolomics in cancer biomarker research Shanghai Jiao Tong University
Education Key Laboratory of Systems Biomedicine
Wang X Curr Pharmacol Rep 2016; 2: 293-298
35 A potential tool for diagnosis of male infertility: Plasma metabolomics base on GC-MS
Central South University
Research Center of Modernization of Chinese Medicines
Zhou X Talanta 2016; 147: 82-89
36 High fasting insulin concentrations may be a pivotal predictor for the severity of hepatic fibrosis beyond the glycemic status in non-alcoholic fatty liver disease patients before development of diabetes mellitus
Kochi Medical School Gastroenterology and Hepatology
Masuda K Hepatology Research 2016 [Epub ahead of print]
37 Global and targeted metabolomics of synovial fluid discovers special osteoarthritis metabolites
Wenzhou Medical University
Biochemistry Zheng K Hepatology Research 2016 [Epub ahead of print]
50 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
Reviews
No. Title Institute Department First Author Citation
1 1,5-Anhydroglucitol : A Novel Serum Marker for Screening and Monitoring Diabetes Mellitus?
Univ. of Pennsylvania Pathology Anne L. Frattali CLIN.CHEM. 1994; 40(11): 1991-1993
2 Serum 1,5-anhydroglucitol(1,5AG): New clinical marker for glycemic control
Teikyo University Medicine II Toshikazu Yamanouchi
Diabetes Res. Clin. Pract. 1994; 24(Suppl.): 261-268
3 Monitoring glycaemic control in diabetic patients Pharmaceutical Medicine 1996; 10: 69-70
4 Intolerancia glicida y diabetes mellitus en el anciano Sixto FT Geriatrika 1997; 13(1): 41-44
5 Laboratory Diagnosis and Monitoring of Diabetes Mellitus Beth Israel Medical Center
Clinical Chemistry Kenneth Emancipator
American Society of Clinical Pathology 1999; 112(5): 665-674
6 1,5-anhydroglucitol (GlycoMarkTM) as a marker of short-term glycemic control and glycemic excursions
Ohio State Univ. Dungan KM Expert Rev. Mol. Diagn. 2008; 8(1): 9-19
7 Serum 1,5-anhydroglucitol (GlycoMark TM): A short term glycemic marker
Univ. North Carolina Buse JB Diabetes Technology & Therapeutics 2003; 5(3): 355-363
8 American college of endocrinology pre-diabetes consensus conference: Part three
Mount Sinai School of Medicine
Endocrinology Bloomgarden ZT
Diabetes Care 2008; 31(12): 2404-2409
9 Assessing postprandial glucose using 1,5-anhydroglucitol: An integrative literature review
Brigham Young Univ. Nursing Christensen BL J Am Acad Nurse Pract 2009; 21(10): 542-548
10 Difficulties in interpreting HbA1c results Pomeranian Medical Univ.
Homa K Polskie Archiwum Medycyny Wewnetrzne J 2010; 120(4): 148-153
11 Determining Glycemic Control Smith J Advance for nurse practitioners 2010; 17(8): 39-40
12 Beyond hemoglobin A1c - need for additional markers of risk for diabetic microvascular complications
Irl B. Hirsch JAMA 2010; 303(22): 2291-2292
13 The clinical use of hemoglobin A1c Johns Hopkins Univ. Saudek CD J Diabetes Sci Technol 2009; 3(4): 629-634
14 Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine
U.S. Air Force Medical Corps
True MW J Diabetes Sci Technol 2009; 3(4): 743-747
15 Reexaming metrics for glucose control University of Washington
Internal Medicine Rubinow KB JAMA 2011; 305(11): 1132-1133
16 The quest for the perfect biomarker of long-term glycemia: new studies, new trials and tribulations
Harvard Medical Center
Endocrinology Joo-Pin Foo Metabolism Clinical and Experimental 2011; 60: 1651-1654
17 The roles of glycated albumin as intermediate glycation index and pathogenic protein
Yonsei University Health System
Kim KJ Diabetes Metab J 2012; 36: 98-107
51 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
18 The challenge of the use of glycemic biomarkers in diabetes: Reflecting on Hemoglobin A1C, 1,5-Anhydroglucitol, and the glycated proteins Fructosamine and Glycated Albumin
Nutrition at the University of Washington
Metabolism, Endocrinology
Wright L.A.-C Diabetes Spectrum 2012; 25(3): 141-148
19 Predicting outcomes and assessing control with alternate glycemic markers
Ohio State University Endocrinology Dungan KM Diabetes Technology & Therapeutics 2012; 14(9): 749-752
20 1,5-Anhydroglucitol in diabetes mellitus Gangneung Asan Hospital
Endocrinology and Metabolism
Kim WJ Endocrine 2013; 43: 33-40
21 Glucose variability Mayo Clinic the Mayo College of Medicine
Service FJ Diabetes 2013; 62(5): 1398-1404
22 Capsule commentary on radin, pitfalls in hemoglobin A1c measurement: When results may be misleading
University of California San Francisco
San Francisco VA Medical Center
Kenneth R J Gen Intern Med 2014; 29(2): 363
23 Glycated albumin - more than the missing link in the evaluation of diabetes control
University of Medicine and Pharmacy Craiova
Dinu IR Rom J Diabetes Nutr Metab Dis. 2014; 21(2): 137-150
24 1,5-anhydroglucitol and glycated albumin in glycemia Municipal Kawanishi Hospital
Diabetes and Endocrinology
Koga M Advances in Clinical Chemistry 2014; 64: 269-301
25 Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management
Johns Hopkins University
Epidemiology Parrinello CM Curr Diab Rep 2014; 14: 548-557
26 Efficacy of voglibose in type 2 diabetes Kawasaki Medical School
Internal Medicine Kaku K Expert Opin. Pharmacother. 2014; 15(8): 1181-1190
27 Glycemic variability: Clinical implications Medwin Hospital Endocrinology Krishna SVS Indian J Endocrinol Metab. 2013; 17(4): 611-619
28 Voglibose: An alpha glucosidase inhibitor Medical College and Sir Sayajirao General Hospital
Medicine Dabhi AS Journal of Clinical and Diagnostic Research 2013; 7(12): 3023-3027
29 Post-prandial hyperglycaemia Indraprastha Apollo Hospital
ACODE Jindal R JIACM 2013; 14(3-4): 242-246
30 Optimizing diabetes management: Comprehensive analysis of glucose monitoring data and use of better metrics for glycemic control
Institute of Diabetes Kohnert KD Biology. Medicine. Geography Series 2013; 4(72): 6-15
31 Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus
Amity University Rajasthan
Amity Institute of Biotechnology
Choudhury SR Current Diabetes Reviews 2014; 10(4): 275-282
32 Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps
Sun Yat-sen University of Medical Science
Guangdong Provincial Key Laboratory of Diabetology
Weng J Diabetes Metab Res Rev 2014; [Epub ahead of print]
52 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
33 Diet and glycaemia: the markers and their meaning. A report of the unilever nutrition workshop
Unilever R&D Alssema M British Journal of Nutrition 2015; 113: 239-248
34 Sodium glucose cotransporter 2 inhibitors Washington State University
Pharmacotherapy White Jr JR Med Clin N Am 2015; 99: 131-143
35 Early phase metabolic research with reference to special populations
Procil Institute for Clinical Research
Morrow LA Translational Research Method for Diabetes, Obesity and Cardiometabolic Drug Development 2015: 225-242
36 Glycemic variability and oxidative stress: A link between diabetes and cardiovascular disease ?
Keio University School of Medicine
Internal Medicine Saisho Y Int. J. Mol. Sci. 2014; 15: 18381-18406
37 Monitoring glycemia in diabetes The Ohio State University Wexner Medical Center
Endocrinology Healy SJ Med Clin N Am 2015; 99(1): 35-45
38 Utility of different glycemic control metrics for optimizing management of diabetes
Institute of Diabetes Kohnert KD World J Diabetes 2015; 6(1): 17-29
39 Amadori albumin in diabetic nephropathy Rajiv Gandhi Center Diabetes and Endocrinology
Neelofar K Indian J Endocrinol Metab. 2015; 19(1): 39-46
40 Insulin initiation: bringing objectivity to choice Bharti Hospital Kalra S Journal of Diabetes & Metabolic Disorders 2015; 14: 17
41 Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol
Inha University Hospital
Pediatrics Lee JE Ann Pediatr Endocrinol Metab. 2015; 20(2): 74-78
42 Glycemic variability: How do we measure it and why is it important ?
Dong-A Medical Center
Endocrinology and Metabolism
Suh S Diabetes Metab J 2015; 39: 273-282
43 Impact of carbohydrates on weight regain University Hohenheim Nutrition Medicine Bosy-Westphal A
Curr Opin Clin Nutr Metab Care 2015; 18(4): 389-394
44 Ethnicity considerations in diagnosing glucose disorders The Alfred Hospital Hare MJL Current Diabetes Reviews 2016; 12(1): 51-57
45 The utility and pitfalls of the currently used measures of glycaemia in the diagnosis and management of diabetes mellitus
Vardhman Mahavir Medical College
Medicine Sharma BD JIACM 2015; 16(3-4): 227-235
46 Glycemic variability and diabetes complications: Does it matter? Of course it dose!
University of Washington School of Medicine
Hirsch IB Diabetes Care 2015; 38(8): 1610-1614
47 Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk
University of Catania Clinical and Experimental Medicine
Pino AD World J Diabetes 2016; 7(18): 423-432
53 M-7-3A
(2017-10-18)
GlycoMark Compendium of Evidence
The GlycoMark test is FDA-cleared for intermediate monitoring of glycemic control in people with diabetes. Please note that these studies may involve findings that discuss indications that are more specific than or beyond those currently cleared by the FDA for the GlycoMark test. This scientific information is NOT presented to make promotional claims about the GlycoMark test. The intent of providing this information is to disseminate the scientific literature currently available about the GlycoMark test. Please read these studies to understand the strengths and limitations of the data. Should you have questions please contact GlycoMark Regulatory Affairs at (888) 744-0221 or [email protected].
No. Title Institute Department First Author Citation
48 Metrics beyond hemoglobin A1C in diabetes management: Time in range, hypoglycemia, and other parameters
University of Washington Medical Center
Medicine Wright L.A.-C Diabetes Technology & Therapeutics 2017; 19(Supplement 2): S16-S26
54 M-7-3A
(2017-10-18)